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CHAPTER I 
 
INTRODUCTION 
 
Serotonin Function and History 
Serotonin (5-hydroxytryptamine, 5-HT) is an indolamine neurotransmitter that is 
involved in many psychophysiological responses such as mood, appetite, aggression, 
arousal, sleep, learning, and motor control (Lentes et al., 1997; Breier, 1995).  It was 
initially identified as a vasoconstricting substance in the blood stream that enhanced 
platelet aggregation in the gut (Rapport et al., 1948).  The highest concentrations of 5-HT 
are found in the gastrointestinal tract where it is made in enterochromaffin cells, followed 
by platelets and the central nervous system (CNS) (Erspamer 1966).  Since serotonin is 
involved in a diverse array of behavioral and physiological processes, defects in 
serotonergic function have been implicated in a number of neuropsychiatric disorders 
including depression, anxiety, eating disorders, suicide, obsessive-compulsive disorder, 
schizophrenia, and migraines (Heisler, 2000).  However, the exact role of 5-HT in these 
diseases is not very well understood. 
 5-HT appeared early in evolution as its distribution can be found throughout both 
the plant and animal kingdoms.  It can be found in the most primitive organisms that 
possess a nervous system such as coelenterates, Platyhelminths (flatworms), 
Caenorhabditis elegans (nematodes), Aplysia californica (mollusks), annelids, 
echinoderms, crustaceans, and Drosophila melanogaster (Weiger, 1997).  In these 
invertebrates, 5-HT modulates many behaviors such as feeding, egg laying, biting, and 
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escape swimming.  The study of these lower organisms have led to great insights into the 
actions of 5-HT as a neurotransmitter, neuromodulator, and neurohormone in both 
invertebrates and vertebrates.  Nonetheless, the mechanisms by which 5-HT affects 
behavior and lead to disease are yet to be clearly understood. 
 
Serotonin Receptor Subtypes 
The physiological effects of 5-HT are elicited through binding to one of fourteen 
receptor subtypes (Barnes and Sharp, 1999).  These receptors are classified into seven 
families based on three criteria: amino acid sequence homology, gene structure, and 
intracellular signaling cascades (Figure 1; Hoyer et al., 1994).  All but one of the 14 
receptor subtypes belong to class A of the superfamily of G protein coupled receptors 
(GPCRs); the 5-HT3 receptor subtype is a ligand gated ion channel.  The 5-HT receptor 
subtypes are the largest of all known neurotransmitter receptor families to date, showing 
the importance and the complexity of the serotonergic system.  Each 5-HT receptor 
subtype has varying affinities for ligands along with different expression profiles 
throughout the body, including the brain.  Therefore, 5-HT can modulate many 
physiological processes depending on the receptor subtype and tissue distribution.  
The 5-HT1 receptor subfamily contains five members all of which are coupled to Gi/Go to 
inhibit the production of adenylyl cyclase to increase K+ conductance and to inhibit 
voltage gated calcium channels (Hoyer et al., 1994).  In mesenchymal cells, 5-HT1 
receptors also mediate stimulatory pathways that include activation of phospholipase Cβ 
(PLCβ) via Gβγ subunits and mitogen-activated protein kinase (MAPK), resulting in cell 
proliferation and transformation (Albert and Tiberi, 2001). 
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Figure 1: Serotonin receptor family
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The 5-HT1A receptor is a somatodendritic autoreceptor on cell bodies of 
serotonergic neurons in the raphe nuclei of the brainstem, where it also activates a 
receptor-operated K+ channel and inhibits a voltage-gated Ca2+ channel via Gβγ subunit 
interaction with the Ca2+ channel’s α1 subunit (Chen and Patterson, 1997).  It is also 
found in target neurons in the hippocampus where its function is less understood.  The 5-
HT1D receptor (homolog to the rat 5-HT1B receptor) is highly expressed in the substantia 
nigra and basal ganglia where it functions as an autoreceptor on axon terminals, 
inhibiting the release of 5-HT. 
 As mentioned earlier, the 5-HT3 receptor is unique in that it is the only member of 
the family and also the only monoamine neurotransmitter receptor known to function as a 
ligand-gated ion channel.  It is found in the CNS in regions such as the cerebral cortex, 
hippocampus, amygdala and medulla and is also found in the peripheral nervous system 
(PNS).  Upon activation, postsynaptic 5-HT3 receptors induce a rapidly desensitizing 
depolarization mediated by the gating of cation influx.  These receptors are also found 
presynaptically where they are thought to modulate neurotransmitter release (Hooft and 
Yakel, 2003).   
 The 5-HT4, 5-HT6, and 5-HT7 receptors all couple to Gs and positively activate 
adenylate cyclase but are divided into different subfamilies based upon lack of sequence 
homology.  The 5-HT4 receptor was first identified in cultured mouse colliculi neurons 
and the guinea pig brain using a functional assay, stimulation of adenylyl cyclase 
(Dumuis et al., 1988; Bockaert et al., 1990).  These receptors are found consistently in the 
nigrostriatal and mesolimbic systems in the brain of many different species (Grossman et 
al., 1993; Mengod et al., 1996).  Four different 5-HT4 receptors variants have been 
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identified as a result of alternative splicing (Gerald et al., 1995; Blondel et al., 1998; 
Claeysen et al., 1998).  Upon activation of 5-HT4 receptors, there is increased neuronal 
excitability and a slowing of repolarization, suggesting that these receptors enhance 
neurotransmitter release (Chaput et al. 1990; Roychowdhury et al., 1994).  The 5-HT6 
receptor was initially identified by two groups after finding a cDNA sequence that 
encoded for a 5-HT sensitive-receptor with distinctive pharmacology (Monsma et al., 
1993; Ruat et al., 1993).  Abundant levels of 5-HT6 mRNA have been detected in the 
caudate nucleus, nucleus accumbens, and hippocampus of human, rat, and guinea pig 
where they are thought to be mostly postsynaptic receptors (Barnes and Sharp, 1999).  
The 5-HT7 receptor is the most recently identified 5-HT receptor.  Although the 5-HT7 
receptor has four splice variants, only three have been found in rat and human tissue, in 
regions such as the thalamus, hypothalamus, and hippocampus (Heidmann et al., 1997).   
 The 5-HT5 receptor is the least understood of all of the receptors in the family.  
The 5-HT5 receptor consists of two members, the 5-HT5A and 5-HT5B receptors.  The 5-
HT5A receptor has been identified in mouse, rat and human (Plassat et al., 1992; Hen, 
1992; Erlander et al., 1993; Wisden et al., 1993; Rees et al., 1994).  However, the 5-HT5B 
receptor is only expressed in the mouse and rat because in the human, the coding 
sequence is interrupted by a stop codon (Grailhe et al., 2001).  For the most part, both 
receptors have their distribution limited to the CNS; 5-HT5A receptors have been found 
on neuronal and neuronal-like cells of the carotid body (Nelson, 2004).  The human 5-
HT5A receptor has been shown to couple to Gi/o proteins to lead to inhibition of adenylate 
cyclase in HEK293 cells (Francken et al., 1998; Hurley et al., 1998). However, the 
physiological function of 5-HT5 receptors is still not clear. 
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5-HT2 Receptors 
 
The 5-HT2 receptor family consists of three subtypes, 5-HT2A, 5-HT2B, and 5-
HT2C receptors which share 46-50% sequence identity.  Through the years, these 
receptors have been renamed 5-HT2A, formerly 5-HT2; 5-HT2B, formerly 5-HT2F; and 5-
HT2C, formerly 5-HT1C.  Most of the homology is within the seven transmembrane 
domains but they are structurally distinct from other 5-HT receptors.  This family is also 
characteristic of coupling positively to the activation of PLC and mobilization of 
intracellular calcium. 
The 5-HT2A receptor was originally classified as the 5-HT D receptor that 
mediated contractions in the guinea pig ileum (Gaddum and Picarelli, 1957).  Brain 5-
HT2A receptors were identified in the rat much later as a binding site with high affinity 
for [3H]-spiperone and low affinity for 5-HT (Leysen et al., 1978; Peroutka and Snyder, 
1979).  The 5-HT2A receptor was cloned from rat brain (Julius et al., 1990) and later from 
humans (Saltzman et al., 1991).  The amino acid sequence of the 5-HT2A receptor has 5 
potential glycosylation sites, 11 phosphorylation sites, and 1 palmitoylation site 
(Saltzman et al., 1991).  Within the PNS, 5-HT2A receptors are found on platelets and in 
the gastrointestinal tract.  In the CNS, 5-HT2A receptors are highly expressed in the 
prefrontal cortex, claustrum, and the caudate nucleus where they function as post-
synaptic receptors (Pazos et al., 1985; Lopez-Gimenez et al., 1997; Aghajanian and 
Marek, 1999).  5-HT2A receptors have been recently characterized electrophyisiologically 
in the raphe nucleus where they are believed to have a pre-synaptic role in regulating 
serotonergic function (Boothman et al., 2003). 
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Although the 5-HT2A receptor has low affinity for 5-HT, it has high affinity for 
the hallucinogenic agonists (±)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane (DOI) 
and lysergic acid diethylamide (LSD).  Until recently, it was difficult to differentiate 
between the 5-HT2 receptors.  However, with the development of selective 5-HT2A 
receptor antagonists such as MDL 100907, we are now able to differentiate these 
receptors in vivo and in vitro (Sorensen et al., 1993).  In addition to the 5-HT2A receptor 
activating PLC, it also activates a biochemical cascade that leads to the altered expression 
of genes such as brain-derived neurotrophic factor (BDNF) (Vaidya et al., 1997).  
Excitatory responses to 5-HT2A stimulation in rat brain slices lead to a reduction in 
potassium conductance (Marek and Aghajanian, 1995). 
The 5-HT2B receptor was the original receptor found to mediate 5-HT-induced 
contraction of the rat stomach fundus with similar pharmacological properties of what is 
now known as the 5-HT2C receptor (Vane, 1959).  The presence of 5-HT2B receptors in 
the brain has been controversial, but they are thought to be present in limited amounts in 
the mouse and human (Loric et al., 1992; Bonhaus et al., 1995).  These receptors are 
restricted to the cerebellum, lateral septum, dorsal hypothalamus, and medial amygdala 
(Barnes and Sharp, 1999).  5-HT2B receptors are thought to mediate in the mitogenic 
effects of 5-HT during neural development. 
The 5-HT2C receptor was identified in the choroid plexus as a [3H]-5-HT binding 
site that could also be labeled with [3H]-mesulergine and [3H]-LSD, but not [3H]-
ketanserin (Pazos et al., 1984).  Because of its high affinity for 5-HT, it was originally 
thought to be a member of the 5-HT1 family and named 5-HT1C.  However, upon cloning 
and further characterization of the receptor, it was reclassified and moved to the 5-HT2 
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family because of its close sequence homology and gene structure and renamed the 5-
HT2C receptor.  The mouse 5-HT2C receptor was first partially cloned by Lubbert et al. 
(1987) followed by sequencing of the full length clone in rat (Julius et al., 1988), the 
mouse (Yu et al., 1991) and then the human (Saltzman et al., 1991; Xie et al., 1996). 
 
Structure and Function of 5-HT2 Receptors 
 GPCRs share many structural features, including seven transmembrane α-helices 
connected by six loops (3 extracellular and 3 intracellular) of varying lengths with an 
extracellular amino terminus and an intracellular carboxyl terminus.  More specifically, 
class A GPCRs are characterized by their sequence homology, which includes shared 
cysteine residues in extracellular loops 1 and 2 (e1 and e2), a DRY motif in intracellular 
loop 2 (i2), and a NPXXY motif in transmembrane 7 (TM 7) (Fig. 2; Bockaert and Pin, 
1999).  Ligand binding takes place on the extracellular or transmembrane domains and 
causes conformational changes that act as a switch to relay the signal to G-proteins that in 
turn induce an intracellular response.  Both mutagenesis and biochemical studies of a 
variety of class A GPCRs suggest that receptor activation by ligand binding causes 
changes in the relative orientation of TM helices 3 and 6 (Wess, 1997; Shapiro et al., 
2002).  To date, the rhodopsin receptor is the only GPCR to be resolved by X-ray 
crystallography at high resolution.  This receptor was crystallized in its inactive form, 
showing the orientation of the seven transmembrane α helices, but the structural 
characteristics of its intracellular loop regions are still lacking (Palczewski et al., 2000).  
Upon receptor activation and interaction with the G-protein, this interaction causes GDP 
to be released by the G-protein.  The receptor contact site on the G-protein is thought to 
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be distant from the GDP-binding pocket, so the receptor must work “at a distance” to 
change the conformation of the protein (Bourne, 1997).  
 Many of the ligands that bind 5-HT2C receptors have polar side chains that need to 
be buried within the membrane in a binding pocket.  In TM 3 of 5-HT2 receptors, a 
conserved aspartic residue (D155) is thought to bind and anchor at least one amine 
moiety in 5-HT and other agonists, thus hiding these polar residues within the membrane 
(Choudhary et al., 1995; Weinstein, 1995).  Site-directed mutagenesis of D155 (D155N) 
revealed that this residue is needed for optimal ligand binding for many agonists and 
antagonists (Wang et al., 1993).  If this aspartic acid is mutated into a glutamic acid 
(D155E), there is a marked decrease in targeting of the receptor to the membrane 
(Kristiansen et al., 2000).  Additional evidence for conserved side chains acting in 
concert to mediate activation comes from mutational studies of aspartic acid residue 
(D120) in TM 2 of the 5-HT2A receptor.  Mutation of the conserved aspartic acid 
(D120N) eliminated coupling while an additional mutation in TM 7 (N376D) restores 
function (Sealfon et al., 1995), suggesting that these residues are adjacent and interact via 
a hydrogen-bonding network.   
 
5-HT2C Receptors 
 
5-HT2C Receptor Distribution 
In contrast to the 5-HT2A and 5-HT2B receptors, there is very little evidence for 
expression of the 5-HT2C receptor outside of the CNS.  Studies using radioligands such as  
[3H]-5-HT, [3H]-mesulergine, and [3H]-LSD to perform autoradiography have provided 
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detailed maps of the distribution of 5-HT2C binding sites in the rat and many other species 
(Pazos et al., 1984).  5-HT2C receptor binding is highest in the choroid plexus where its 
function is still not clear, but is also present in areas of the cortex (olfactory nucleus, 
pyriform, cingulate, and retrosplenial), limbic system (amygdala, nucleus accumbens, and 
hippocampus), and the basal ganglia (caudate nucleus and the substantia nigra).  The 
existence of 5-HT2C receptor binding in the pyriform cortex and the substantia nigra, 
support the findings of 5-HT2C receptor-mediated electrophysiological responses in these 
regions (Sheldon and Aghajanian, 1991; Rick et al., 1995).   
 For the most part, there is good correlation between the distribution of 5-HT2C 
receptor mRNA and 5-HT2C receptor binding sites (Mengod, 1990).  However, one 
exception is the high levels of 5-HT2C receptor mRNA in the lateral habenular nucleus 
where 5-HT2C receptor binding sites are very low.  Therefore, 5-HT2C receptors may be 
presynaptically located based upon the projections of the habenula.  It has also been 
reported that the distribution of the 5-HT2C receptor-like immunoreactivity also follows 
the binding data (Abramowski et al., 1995).  5-HT2C receptor mRNA has been reported in 
the midbrain raphe nuclei in two studies (Hoffman and Mezey, 1989; Molineaux et al., 
1989), however, these results were not confirmed in another study (Mengod et al., 
1990b).  A recent study used double in situ hybridization to examine the cellular 
localization of 5-HT2C receptor mRNA in relation to serotonergic and GABAergic 
neurons in the anterior raphe nuclei of the rat (Serrats et al., 2005). In the dorsal and 
median raphe nuclei, 5-HT2C receptor mRNA was not detected in serotonergic neurons, 
however, it was found in most GABAergic cells. Together, these data provide evidence 
that the 5-HT2C receptor is located both on the presynaptic and postsynaptic terminal. 
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5-HT2C Receptor Pharmacology 
 The pharmacological profile of the 5-HT2C receptor is similar to but 
distinguishable from other members of the 5-HT2 receptor family (Baxter et al., 1995).  
5-HT has a higher affinity for the cloned human 5-HT2C receptor (Kd = 2-56 nM) than for 
the 5-HT2A receptor (Kd = 63-250 nM).  The antagonists ritanserin, LY 53857, 
mesulergine, mianserin and the agonists m-chlorophenylpiperazine (mCPP) and DOI do 
not discriminate well between the different 5-HT2 receptors.  On the other hand, the 5-
HT2B/2C receptors can be distinguished from the 5-HT2A receptor by their high affinity for 
SB 200646 and SB 206553, and for their low affinity for the antagonists MDL 100907, 
ketanserin, and spiperone (Table 1).  Additionally, the novel compound SB 204741 is 
approximately 20-60 fold more selective for the 5-HT2B receptor over the 5-HT2C 
receptor.  The development of the recent selective antagonists SB 242084 and RS-102221 
have been profound in the study of 5-HT2C receptors because these compounds are at 
least two orders of magnitude more selective for the 5-HT2C receptor versus the 5-HT2A, 
5-HT2B, and other binding sites (Bonhaus et al., 1997; Kennett et al., 1997).  The typical 
and atypical antipsychotics chlorpromazine, clozapine, loxapine all have relative high 
affinity for both 5-HT2C and 5-HT2A binding sites as well as some antidepressants (e.g. 
tricyclics, doxepin, mianserin, and trazadone) (Canton et al., 1990; Roth et al., 1992; 
Jenck et al., 1993). 
Not only does 5-HT2C receptor have a high affinity for 5-HT, it is also able to 
exhibit complex binding consistent with multiple affinity states.  In stable cell lines 
expressing the 5-HT2C receptor, competition binding experiments using 5-HT to compete 
off [3H]-mesulergine exhibited shallow curves.  In order to determine if the shallow 
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Table 1:  Preference for various 5-HT2 antagonists at human 5-HT2 receptors 
Ki values are in nM; pA2 values were determined in rat fundus preparations. 
 
 5-HT2A 5-HT2B 5-HT2C Reference 
5-HT2A 
preferring 
    
Risperidone  0.4 29 64 Wainscott et 
al., 1996 
Pirenperone  1.1 61 77 Wainscott et 
al., 1996 
Spiperone  1.4 590 3,830 Ismaiel et al., 
1996 
Ketanserin  2.0 395 160 Wainscott et 
al., 1996 
MDL 11,939  6.1 3,020 1,020 Wainscott et 
al., 1996 
AMI-193  7.7 710 8,495 Ismaiel et al., 
1996 
MDL 100907 0.85 261 136 Kehne et al., 
1996 
     
5-HT2B 
preferring 
    
LY23728  66 1 123 Audia et al., 
1996; Bonhaus 
et al., 1999 
LY266097  19 pA2 = 9.80 25 Audia et al., 
1996 
SB 204741  >10,000 79 2,000 Bonhaus et al., 
1995 
     
5-HT2B/2C 
preferring 
    
SB 206553  1,600 pA2 = 8.48 10 Forbes et al., 
1995 
SB 200646   >10,000 630 400 Bonhaus et al., 
1995 
SDZ SER-082  630 pA2 = 7.34 16 Nozulak et al., 
1995 
SB 242084 300 100 1 Kennett et al., 
1997 
RS-102221 1,122 813 3.8 Bonhaus et al., 
1997 
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curves for agonists were due to multiple affinity states or multiple binding sites, a non-
hydrolysable form of GTP, (GppNHp), was used, which eliminates high affinity agonist 
binding.  This was found to be the case for the unedited form of the 5-HT2C receptor but 
only with 5-HT (Niswender et al., 1999).  More recent data suggests the unedited (INI) 
and edited (VSV) isoforms of the 5-HT2C receptor are able to bind 5-HT, DOI, and mCPP 
with multiple affinity states (Fentress et al., 2005).  Although LSD has a high affinity for 
the 5-HT2C receptor, it has not been demonstrated to bind with multiple affinity states. 
 
Intracellular Signaling of 5-HT2C Receptors 
 Originally, it was thought that receptor activation resulted in a single intracellular 
signaling pathway initiating a cellular response.  However, the 5-HT2C receptor, like 
many other GPCRs, is able to activate numerous signaling pathways by interacting with 
multiple G-proteins.  Traditional activation of the 5-HT2C receptor activates 
phospholipase C (PLC) in the choroids plexus of various species (Sanders-Bush et al., 
1988) and stably transfected cells (Julius et al., 1988) by coupling to the G-protein, Gq 
(Fig. 3; Chang et al., 2000).  PLC then promotes the hydrolysis of the membrane 
phospholipid, phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) 
and inositol 1,4,5-triphosphate (IP3).  DAG then goes on to activate protein kinase C 
(PKC) while IP3 activates intracellular calcium stores (Figure 4; Sanders-Bush et al., 
1990).  The activation of intracellular calcium stores activate calcium-dependent 
calmodulin kinases leading to the inactivation of potassium channels.  Calcium release 
may also lead to the activation of chloride currents.  The second messenger DAG may 
also release arachidonic acid (AA) that can result in elevated cGMP levels (Fig.4). 
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In addition to activating PLC, 5-HT2C receptors also activate phospholipase A2 
(PLA2) (Fig.4).  Activation of PLA2 via a pertussis toxin-insensitive G-protein(s), results 
in the release of arachidonic acid from various membrane phospholipids.  Arachidonic 
acid has many cellular functions of its own and is also metabolized to a myriad of 
bioactive compounds (eicosanoids) such as prostaglandins, leukotrienes, and 
thromboxanes.  In transfected CHO cells, 5-HT1B receptor-mediated inhibition of 
forskolin-stimulated cAMP accumulation is inhibited by 5-HT2C receptors by increasing 
arachidonic acid via a PLA2 mechanism.  Although the 5-HT2A has also been found to 
activate PLA2, it was unable to inhibit 5-HT1B receptor activation in CHO cells (Berg et 
al., 1996; Berg et al., 1998).  
 The 5-HT2C receptor has also been shown to increase cGMP (Fig. 4) in pig 
choroid plexus tissue slices.  This activation was insensitive to the treatment with 
pertussis toxin but was sensitive to calcium.  5-HT2C receptor cGMP activation is thought 
to be dependent upon PLA2 and lipoxygenase since inhibitors of either protein 
significantly decreased cGMP production (Kaufman et al., 1995).  However, it is still not 
clear whether or not cGMP formation is secondary to PI turnover although the reverse 
has been ruled out (Conn and Sanders-Bush, 1986).  In the choroid plexus, the non-
selective 5-HT2 receptor agonists TFMPP, quipazine, DOM, mCPP, and MK 212 all 
behave as agonists.  However, only MK 212 had an equal efficacy to 5-HT (Conn and 
Sanders-Bush, 1987; Sanders-Bush et al., 1988).  It is thought that 5-HT2C receptors in 
the choroid plexus may regulate CSF formation as a result of their ability to mediate 
cGMP formation (Kaufman et al., 1995). 
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Activation of endogenous 5-HT2C receptors in choroid plexus epithelial (CPE) 
cells leads to the stimulation of phospholipase D (PLD) (Fig. 4).  This effect is blocked 
by the 5-HT2C specific antagonist SB206553 but not by the 5-HT2A specific antagonist 
MDL100907.  5-HT2C receptor activation of PLD is mediated through coupling to the G13 
protein and activation of the small G-protein Rho.  These interactions were further 
characterized and found to be a result of both Gα and Gβγ subunits from G13 (McGrew et 
al., 2002).  PLD activation has been suggested to be a mediator of stress fiber formation 
(Gohla et al., 1999), and has also been linked to vesicle trafficking (Brown et al., 1993; 
Malcolm et al., 1994), the formation of oxygen radicals (Grewal et al., 1999), and cell 
cycle control (for review see Exton, 1999).   
 
Constitutive Activity of 5-HT2C Receptors 
 Some antagonists have been found to possess negative intrinsic activity, meaning 
its affinity for receptors is increased following uncoupling from G-proteins.  The 
phenomenon of negative intrinsic activity was first recognized in the actions of β-
carbolines at the ionotropic GABAA receptor (Braestrup et al., 1982).  The ability to 
detect negative intrinsic activity depends upon a measurable amount of constitutive or 
agonist-independent activity.  Constitutively active receptors are receptors that are able to 
undergo a conformation change in the absence of agonist that allows coupling to G-
proteins, thereby activating a signaling cascade.  This phenomenon has been found to 
occur at many GPCRs including the 5-HT2C receptor (Barker et al., 1994).   
Importantly, studies of constitutively activating mutations have provided insight 
into the role of specific side chains in receptor activation.  As one may not expect, most 
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activating mutations do not occur in conserved regions.  Mutation of the non-conserved 
Ala293 in the α1B adrenergic receptor to any amino acid yields a constitutively active 
receptor (Kjelsberg et al., 1992).  Other studies have shown that mutations of the 
conserved Asp-Arg domain at the cytoplasmic boundary of TM 3 cause constitutive 
activity in some GPCRs (Scheer et al., 1997; Fanelli et al., 1999).  In addition, the Tyr368 
in the conserved Asn-Pro-X-X-Tyr motif in TM 7 has been studied in many GPCRs, and 
found to affect agonist affinity, signaling, and sequestration in different receptors (Barak 
et al., 1995; Gabilondo et al., 1996).  Constitutively active GPCRs have also been created 
in vitro by site-directed mutagenesis in several transmembrane domains, extracellular and 
intracellular loops.  Specifically, constitutive receptor activation has been achieved by 
mutating amino acid residues in i2, i3, TM 3, and TM 5 of adrenergic receptors 
(Kjelsburg et al., 1992; Scheer et al., 1996; Hwa et al., 1997), TM 6 of the M5 muscarinic 
receptor (Spalding et al., 1995), and e1, e2, i3, TM 2, TM 3, TM 6, and TM 7 of the TSH 
receptor (Tonacchera et al., 1996), and e2 of the thrombin receptor (Nanevicz et al., 
1996).  As for the 5-HT2C receptor, mutation of the Tyr368 to a cysteine or alanine in this 
conserved domain in TM 7 resulted in a marked increase in basal PI hydrolysis which 
was abolished by the addition of the inverse agonist SB 206553.  Introduction of a 
phenylalanine to this locus eliminated both basal and agonist-stimulated signaling.  All 
three mutations caused an increase in binding affinity for the structurally different 
agonists 5-HT, DOI, and quipazine, suggesting that both the activating and inactivating 
mutations stabilize a high affinity state (Rosendorff et al., 2000).  These data suggest that 
this conserved Tyr368 has both a structural and functional role in 5-HT2C receptor. 
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5-HT2C receptor antagonists such as mianserin and mesulergine have been shown 
to have negative intrinsic activity, as evidenced by a decrease in agonist-independent, 
receptor mediated PI hydrolysis in transfected cells.  The antagonists ketanserin and 
spiperone also caused dose-dependent decreases in basal PI hydrolysis.  On the other 
hand, BOL did not reduce basal activity; although it did block 5-HT’s actions completely.  
BOL was also able to prevent the decreased in basal activity produced by mianserin and 
mesulergine.  These findings combined with the fact that the antagonists had no effect in 
untransfected cells indicate that the decrease in basal was receptor-mediated.  Therefore, 
it was concluded that mianserin, ketanserin, mesulergine, and spiperone act as inverse 
agonists at 5-HT2C receptors, with varying degrees of negative intrinsic activity, while 
BOL acts as a neutral antagonist (Barker et al., 1994).  Moreover, in the revised ternary 
complex model of G-protein coupled receptors, inverse agonists are preferred to bind and 
stabilize a coupling-inconcomitant conformation. 
 In order to mimic the active conformation of the 5-HT2C receptor, serine 312 in i3 
was mutated to a phenylalanine (S312F) or lysine (S312K).  Upon expression of the 
mutant receptors into cells, the Ki values of 5-HT for [3H]-mesulergine-labeled 5-HT2C 
receptors decreased from 203 nM (native) to 76 nM for S312F and 6.6 nM for S312K 
mutant receptors.  The potency of 5-HT for stimulation of PI hydrolysis increased (EC50= 
70 nM, 28 nM, and 2.7 nM respectively).  These mutant receptors were also 
constitutively active, stimulating PI hydrolysis in the absence of agonist.  The S312F and 
the S312K mutants resulted in two-fold and five-fold increases, respectively, in basal 
levels of PI hydrolysis.  Mianserin and mesulergine both displayed inverse agonist 
activity by decreasing basal levels of PI hydrolysis stimulated by the S312K mutants.  
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[3H]5-HT and [3H]-mesulergine labeled the same number of S312K mutant receptors and 
5΄-guanylylimidodiphosphate (Gpp(NH)p) had no effect on [3H]5-HT binding.  These 
results indicate that the S312K mutation produces an agonist high affinity state of the 5-
HT2C receptor that spontaneously couples to G-proteins and stimulates PI hydrolysis in 
the absence of agonist to a greater level than normal (Herrick-Davis et al., 1997). 
 
Homodimerization of the 5-HT2C Receptor 
 GPCR dimerization is an emerging area of research on the molecular mechanisms 
of receptor activation.  The first studies examining GPCR dimerization used membrane 
solubilization and Western blotting and were criticized because of the potential for non-
specific protein aggregation during membrane preparation and solubilization.  Another 
issue was the fact that the higher molecular weight bands observed on Western blots, 
presumed to be receptor dimers/oligomers, were insensitive to detergents and reducing 
agents.  However, subsequent studies using techniques such as co-immunoprecipitation 
(Hebert et al., 1996; Romano et al., 1996; Zeng et al., 1999) and biophysical techniques 
(Angers et al., 2000; Rocheville et al., 2000; Kroeger et al., 2001) have provided stronger 
evidence of GPCR formation of dimers/oligomers. 
 The first evidence that 5-HT receptors may form homodimers was provided by 
Western blots of solubilized membrane protein from Sf9 insect cells expressing 5-HT1B 
or 5-HT1D receptors (Ng et al., 1993; Xie et al., 1999).  In a later study, co-
immunoprecipitation of differentially tagged 5-HT1A, 5-HT1B, and 5-HT1D receptors 
suggested that 5-HT1 receptors may form heterodimers (Salim et al., 2002).  There have 
been no reports demonstrating the presence of 5-HT receptor dimers/oligomers on the 
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plasma membrane of live cells until the recent report by Herrick-Davis et al. (2004).  In 
their study, using biochemical and biophysical techniques, they examined the ability of 
the 5-HT2C receptor to form homodimers on living cells.  Immunoprecipitation followed 
by Western blotting revealed the presence of immunoreactive bands the predicted size of 
5-HT2C receptor monomers and homodimers that were detergent and cross-linker 
sensitive.  In HEK293 cells expressing 5-HT2C receptors labeled with Renilla luciferase 
and yellow fluorescent protein, bioluminescence resonance energy transfer (BRET) was 
accessed.  BRET levels were not altered by pretreatment with 5-HT.  With confocal 
microscopy, they were able to directly visualize fluorescent resonance energy transfer 
(FRET) on the plasma membrane of living cells expressing 5-HT2C receptors labeled with 
cyan (donor) and yellow (acceptor) fluorescent proteins.  FRET, accessed by acceptor 
photobleaching, was dependent on the donor/acceptor ratio and independent of acceptor 
expression levels.  This indicated that FRET resulted from receptor clustering and not 
from overexpression of randomly distributed receptors, providing evidence for GPCR 
dimers/oligomers in a clustered distribution on the plasma membrane.  Together, these 
results suggest that 5-HT2C receptors exist as constitutive homodimers on the plasma 
membrane of living cells. 
 
Electrophysiological Responses 
 There is also evidence for the 5-HT2C receptor mediated excitation of neurons in  
certain brain regions.  Particularly, neurons in the rat substania nigra reticulata in vitro are 
excited by 5-HT and this response can be blocked by ketanserin and methysergide but not 
spiperone or selective antagonists of 5-HT1, 5-HT3, and 5-HT4 receptors (Rick et al., 
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1995).  In the rat pyriform cortex, activation of 5-HT2C receptors leads to depolarization 
of pyramidal neurons.  The response of these neurons to 5-HT was blocked by spiperone, 
ritanserin, and LY 53857 but at concentrations that appeared to be somewhat higher than 
those need to block the 5-HT2A receptor mediated responses in the same preparation 
(Sheldon and Aghajanian, 1991).   
 Motor neurons of the facial nucleus in vitro and in vivo are activated by the local 
application of 5-HT and 5-HT2 receptor agonists.  This effect may be mediated by the 5-
HT2C receptor (for review see Aghajanian, 1995).  In earlier in vitro studies in the 
response of these neurons to 5-HT was block by methysergide, but not ketanserin or 
spiperone (Larkman and Kelly, 1991).  On the other hand, other studies have shown that 
excitation of facial motor neurons by 5-HT and other 5-HT agonists were blocked by 
ritanserin and spiperone (Aghajanian, 1995).  However, the lack of 5-HT2A receptor-like 
immunoreactivity in the rat facial nucleus suggests that the physiological factors are non-
5-HT2A mediated; presumably 5-HT2C receptors (Morilak et al., 1993).  The development 
of more 5-HT2 subtype specific agonists will aid in solving these problems. 
 
Behavioral and other Physiological Repsones 
 Several behavioral responses have been shown to be associated with activation of 
central 5-HT2C receptors.  These include hypolocomotion, hyperphagia, anxiety, penile 
erections, and hyperthermia (for review see Koek et al., 1992).  Most of these 
associations are based upon behavioral effects seen in rats with non-selective 5-HT2 
receptor agonists such as mCPP, TFMPP, and MK 212 along with antagonism by non-
selective 5-HT2 antagonists such as mianserin and ritanserin.  However, the evidence for 
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involvement for the 5-HT2C receptor in these behaviors is becoming convincing as we 
continue to study these behaviors with more specific ligands and the use of transgenic 
animal models. 
 Although the agonists mCPP and TFMPP are partial agonists at the 5-HT2C 
receptor, these compounds normally have antagonistic properties at the 5-HT2A receptor 
(Conn and Sanders-Bush, 1987; Baxter et al., 1995).  Futhermore, 5-HT2A receptor 
antagonists such as ketanserin are generally inactive against mCPP responses (Koek et 
al., 1992).  The 5-HT2C receptor’s role in mCPP-induced hypophagia is further supported 
by the fact that the 5-HT2C receptor knockout mice are obese (Tecott et al., 1995).  
Additionally, mCPP-induced hyperphagia, hypolocomotion, and anxiety are all 
antagonized by the 5-HT2C/2B antagonists SB 200646 or SB 206553 (Kennett et al., 1994, 
1996).  The 5-HT2C receptor selective antagonist SB 242084 also potently blocks mCPP-
induced hypolocomotion and hypophagia (Kennett et al., 1997).  When 5-HT2C receptor 
antagonists are given alone, they are anxiolytic in various animal models (Kennett et al., 
1996, 1997).  However, evidence suggests that normal animals treated with these 
antagonists do not over-eat or have a high propensity for epileptic seizures, even though 
these are hallmark features of the 5-HT2C receptor knock mice (Tecott et al., 1995).  
Therefore, the phenotypes in the knock out mice may be a result of developmental 
abnormalities versus a loss of the receptor in adult mice (Kennett et al., 1997; Bonhaus et 
al., 1997). 
 There is also evidence that 5-HT2C receptors are able to regulate the release of 
other neurotransmitters.  Antagonists of these receptors have been reported to increase 
the release of noradrenaline and dopamine in microdialysis experiments (Millan et al., 
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1998; Di Matteo et al., 1998) and via in vivo extracellular single cell recording 
(Blackburn et al., 2002).  These data suggest that 5-HT2C receptors have a tonic inhibitory 
effect on mesocortical/mesolimibic dopaminergic and noradrenergic projections.  
Corticosterone and ACTH responses to mCPP in rats may be mediated by the 5-HT2C 
receptor (Fuller, 1996).  In humans, mCPP-induced prolactin secretion involves the 5-
HT2C receptor (Cowen et al., 1996).  Blockade of 5-HT2C receptors in human, causes 
increase in slow wave sleep (Sharpley et al., 1994).   
 
Molecular Diversity: Regulation at the Level of RNA processing 
Proteins are able to generate molecular diversity through processing mechanisms 
at various levels, including at the RNA level.  This enables many protein isoforms to be 
generated with different functions from a single gene product.  Two RNA processing 
events that alter the 5-HT2C receptor are RNA splicing and RNA editing.  These 
processes together generate diverse 5-HT2C receptor isoforms with altered functions. 
 
RNA Splicing 
 The genes for both the 5-HT2A and 5-HT2C receptors undergo alternative splicing 
of their pre-mRNAs.  This process entails removal of introns in more than one way 
before RNA translation.  Most of the nucleotide sequences around the intron begin at the 
5΄-end with a GU dinucleotide sequence and terminate at the 3΄-end with an AG 
dinucleotide sequence.  These, as well as other consensus sequences attract the 
spliceosome, a molecular complex essential to splicing of the introns and ligation of the 
exons.  As these introns are spliced out of the nascent RNA at alternative splice sites, 
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multiple protein isoforms result from a single gene locus.  To date, all of the protein 
isoforms generated by alternative RNA splicing of the 5-HT2A and 5-HT2C receptors 
encode pharmacologically inactive proteins.  For example, the 5-HT2A receptor is 
alternatively spliced producing a variant RNA with a 112-base insert which results in a 
frame shift and a premature stop codon (Guest et al., 2000).  Consequently, this transcript 
encodes a nonfunctional, truncated protein that terminates in the region of TM 4.  While 
it is possible that the truncated protein could interact with the full-length 5-HT2A receptor 
protein in a dominant-negative manner to regulate its function, careful evaluation of this 
phenomenon indicated that this is not the case (Guest et al., 2000). 
 The 5-HT2C receptor has two alternative splice variants.  The first one discovered 
has a 96-bp deletion that occurs at the junction of exon II and III, resulting in a protein 
that is truncated near the putative junction of the second intracellular loop and TM 4 
(Canton et al., 1996; Xie et al., 1996).  The full-length and the truncated mRNAs are 
expressed in parallel throughout the brain.  Studies examining the function of the 
truncated protein expressed alone or in combination with the full-length protein suggest 
that the splice variant is inactive.  The second splice variant was identified by Wang et al 
(2000).  This splice variant had a truncated C-terminus that displayed no ligand binding 
capability or G-protein coupling activity.  Upon further examination of the truncated 
splice variant, the data suggested that RNA editing of this variant occurred after 
completion of splicing, resulting in complete editing at all five sites (Wang et al., 2000). 
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RNA Editing:  Definition and Historical Overview 
A second less common mechanism for creating protein diversity at the level of 
RNA processing is the relatively recently discovered process, RNA editing.  RNA editing 
was initially described as a phenomenon in which uridine residues were inserted or 
deleted from mitochondrial RNAs of kinetoplastid protozoa (Benne et al., 1986).  Now 
this process is broadly defined as any event that changes the coding potential of primary 
RNA transcripts by mechanisms other than RNA splicing.  The most common form of 
editing involves substitution of nucleotides and this phenomenon has been observed in 
the mouse and a viral pathogen that affects humans (Samuel, 2003).  The nucleotide 
substitution consists of either cytidine-to-uridine (C-to-U) or adenosine-to-inosine (A-to-
I) alterations which may result in altered coding potential of the mRNA and altered 
function of the encoded protein.   
Transcripts in the mouse intestine encoding apolipoprotein B (apoB) were the first 
example of RNA editing on a nucleus encoded mRNA. In apoB, cytidine at the C4 
position is converted to uridine by a specific cytidine deaminase.  This deamination 
converts a glutamine codon (CAA) into a stop codon (UAA), thereby producing a novel 
apoB protein isoform with distinct physiological properties in comparison to the full 
length protein (Davidson, 1993).  A tripartite regulatory sequence surrounding the edited 
cytidine residue along with a multi protein complex called an editosome is required for 
this modification to take place (Gott and Emeson, 2000).  This C-to-U change can be 
easily detected.  In contrast, A-to-I editing is more difficult to detect. 
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RNA Editing of Glutamate Receptor Subunits 
The AMPA subtype of the glutamate receptor is composed of four subunits, 
GluR-A, -B, -C, and –D which can form homomeric and heteromeric ligand-gated ion 
channels (Hollmann et al., 1989; Keinanen et al., 1990; Dingledine et al., 1999).  
Comparisons between genomic and cDNA sequences of transcripts encoding subunits of 
the GluR-B receptor revealed adenosine-to-guanosine changes.  It was later found that 
these discrepancies actually resulted from the enzymatic deamination of adenosine 
residues to inosines.  Inosines have base pairing properties similar to guanosines; 
therefore they are translated as guanosines by the decoding ribosomes (Higuchi et al., 
1993; Melcher et al., 1995).  This modification involves the hydrolytic deamination of 
adenosine at the C6 position of the purine ring (Melcher et al., 1995; Polson et al.1994).  
A-to-I editing requires short complementary RNA sequences embedded in an adjacent 
intron to form an imperfect RNA duplex with the exonic target sequence around the 
adenosine to be deaminated (Seeburg, 2002).  Given that A-to-I editing may occur in 
introns of pre-mRNAs and intron-exon base pairing interactions are required, it is clear 
that RNA editing is a nuclear event that precedes splicing (Higuchi et al., 1993).  
 The presence or absence of the GluR-B subunit defines the divalent cation 
permeability of the AMPA receptor (Hollmann et al., 1991).  AMPA receptors with the 
GluR-B subunit are impermeant to calcium ions while those without the subunit increase 
their permeability to calcium. RNA editing of the GluR-B determines its calcium 
permeability, suggesting that RNA editing process is a significant regulatory mechanism 
for neuronal activation and signaling (Verdoorn et al., 1991).  Editing occurs at a specific 
arginine residue within the second transmembrane (TM2) region of the protein.  
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Nucleotide sequence analysis revealed an arginine (CGG) codon in GluR-B cDNAs, 
while a glutamine (CAG) codon was found in the GluR-B genomic DNA (Sommer et al., 
1991).  Southern analyses of genomic DNA ruled out multiple genes or alternative 
splicing of the arginine codon, leaving the hypothesis that RNA editing caused the base 
change (Sommer et al., 1991).  Later it was found that this discrepancy resulted from 
conversion of an adenosine to inosine (Rueter et al., 1995).  The GluR-B receptor is 
edited nearly 100% of the time, thus dictating the calcium impermeability of this ion 
channel.  The subunits of heteromeric kainate receptors (GluR-5 and GluR-6) have also 
been shown to be regulated by RNA editing (Sommer et al., 1991; Kohler et al., 1993). 
 
Adenosine Deaminases that act on RNA (ADAR1) 
 Even before the discovery of the editing in the GluR-B subunit of the glutamate 
receptor, an activity that unwinds double-stranded RNA (dsRNA) was identified and 
described in Xenopus laevis (Bass and Weintraub, 1987).  Later studies discovered that 
instead of unwinding duplex RNA, this activity catalyzed the conversion of adenosine to 
inosine by way of hydrolytic deamination (Polson et al., 1991).  This enzymatic activity 
causes the RNA to become more single stranded by converting the stable A-U base pairs 
to less stable I-U pairs, ultimately leading to destabilization of the RNA duplex (Bass and 
Weintraub, 1988).  For several years, this enzyme became known as dsRNA-specific 
adenosine deaminase (dsRAD or DRADA), and is now referred to as adenosine 
deaminases that act on RNA (ADAR1) (Reuter and Emeson, 1998).  Two other ADARs 
(ADAR2 and ADAR3) have been clone with unique substrate specificity and regional 
localization.  
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RNA Editing of the 5-HT2C Receptor 
Editing of the 5-HT2C receptor was discovered by comparing sequences from rat 
genomic DNA and cDNAs from the striatum; four A-to-G discrepancies were identified.  
The cDNA library predicted the presence of valine (GTG), serine (AGT), and valine 
(GTT) (5-HT2C-VSV) at positions 157, 159, and 161 respectively.  Conversely, the 
genomic DNA was found to be encoded by isoleucine (ATA), asparagine (AAT), and 
isoleucine (ATT) (5-HT2C-INI) at these three positions (Burns et al. 1997).  As a result, it 
was proposed that the four adenosine residues in the 5-HT2C receptor RNA (Fig. 5; sites 
termed A, B, C, and D) were converted into inosines in the mature mRNA by a process 
analogous to that seen for editing of the subunits of the AMPA and kainate glutamate 
receptors.  Further analysis of cDNA sequences isolated from rat brain revealed the tissue 
specific expression of seven major 5-HT2C receptor isoforms, encoded by eleven distinct 
RNA species.  The most prominent variant found in whole rat brain extracts was encoded 
by editing at the A, B, and D sites and expressed the 5-HT2C-VNV receptor protein (Fig. 6).  
On the other hand, editing at the A and B sites was reduced in choroid plexus, thus 
generating high levels of the 5-HT2C-INI, 5-HT2C-INV, and 5-HT2C-ISV receptor variants 
(Burns et al., 1997).  In the human brain, a novel editing site was found and termed E 
(previously named C') (Fig. 5).  This modification occurs at codon 158, converting the 
asparagine into a glycine resulting in the fully edited 5-HT2C-VGV protein (Niswender et 
al., 1999).  These editing events take place in the putative second intracellular loop of the 
receptor (Burns et al., 1997); thereby altering the coding potential in a region implicated 
in receptor:G-protein coupling (Arora et al., 1995; Blin et al., 1995; Arora et al., 1997). 
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Molecular Mechanisms of 5-HT2C Receptor RNA Editing 
The family of adenosine deaminases that act on RNA (ADAR) consists of three 
members; ADAR 1 and 2, which are ubiquitously expressed, and ADAR3, which is 
highly enriched in brain.  These enzymes bind specifically to double-stranded RNA and 
catalyze the conversion of adenosine to inosine by hydrolytic deamination. Analysis of 
DNA from the rat 5-HT2C receptor gene, in the region surrounding the potential editing 
sites, suggested the existence of an imperfect inverted repeat forming a putative RNA 
duplex between the 3' end of exon 3 and the proximal region of intron 3 (Fig. 7; Rueter 
and Emeson, 1998).  This region is conserved between human and rodents.  In order to 
study the molecular mechanisms of the post-transcriptional modification of 5-HT2C 
receptor transcripts, Burns et al. (1997) developed an in vitro editing system using rat 
brain nuclear extracts fractionated by cation-exchange chromatography and a 5-HT2C 
receptor RNA substrate labeled with [α-32P] adenosine 5'-triphosphate.  These 
experiments revealed two peaks of inosine that co-eluted with two distinct peaks of 
editing activity.  Activity of the first peak was responsible for editing 5-HT2C receptor 
transcripts at sites A, B, and C and co-eluted with the activity of ADAR1, which has also 
been shown to modify the B subunit of AMPA glutamate receptors (Yang et al., 1995).  
The second peak of activity specifically modified the D site of the transcripts and co-
eluted with the activity of ADAR2, the enzyme that has been shown to modify the Q/R 
site of GluR-B (Maas et al., 1996).   
 
Functional Consequences of 5-HT2C Receptor Editing 
Since editing of the 5-HT2C receptor occurs in a region involved in G-protein 
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Figure 7: Rat 5-HT2C receptor RNA duplex structure 
(Rueter and Emeson, 1998). 
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coupling, it was hypothesized that this post-transcriptional modification may alter 
receptor function.  In order to test the functional consequences of RNA editing, NIH-3T3 
fibroblasts were transfected with different 5-HT2C receptor isoforms and their ability to 
activate phospholipase C (PLC) was assayed.  The rat 5-HT2C-VSV isoform displayed 10-
15 fold lower potency upon 5-HT stimulation compared to the unedited 5-HT2C-INI 
isoform.  Affinity changes, desensitization, and spare receptors were all ruled out as 
possible explanations for these differences, leaving reduced receptor G-protein coupling 
as the mechanism for the alteration in potency (Burns et al., 1997).  The pattern of editing 
in human brain differs from that found in rat, principally due to increased editing at the C 
and E positions.  This leads to the production of the 5-HT2C-VSV isoform as the most 
prominent variant in human brain as opposed to 5-HT2C-VNV in the rat (Fig. 7; Niswender 
et al., 1999; Fitzgerald et al., 1999).  The human 5-HT2C-VSV receptor exhibited a 5-fold 
shift in potency for 5-HT when compared to the 5-HT2C-INI receptor (Niswender et al., 
1999), while the human 5-HT2C-VGV variant showed an even greater shift (29-fold) (Fig. 
8).  It was also found that the 5-HT2C-INI receptor existed in a high and low affinity state 
for 5-HT, while the 5-HT2C-VGV receptor lost the agonist high affinity state (Niswender et 
al., 1999).  The 5-HT2C-VGV receptor was also unable to stimulate inositol phosphate 
formation in the absence of agonist, a property referred to as constitutive activity that has 
been well established to occur at both the rat and human 5-HT2C-INI receptors (Barker et 
al., 1994).  Price and Sanders-Bush (2000) later showed that editing also delayed agonist- 
stimulated calcium release.  Taken together, these functional data in cell lines show that 
unedited 5-HT2C receptors couple more efficiently to G proteins even when no agonist is 
presence, suggesting that editing may be a way to decrease tone and signaling in certain 
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brain regions.  More recently, studies of the profile of G protein coupling utilizing a high 
throughput functional assay have demonstrated that not only is coupling efficiency 
reduced, but also, the pattern of G protein coupling is altered (Price et al.,  2001).  The 5-
HT2C-INI receptor isoform couples to Gq/11, as well as, to G13.  The 5-HT2C-VGV and 5-
HT2C-VSV receptor isoforms have loss the ability to couple to G13 and this in turn leads to 
altered intracellular signaling (Fig. 9).  
 In order to determine the role of RNA editing in drug response, cell lines 
expressing variant 5-HT2C receptor isoforms were tested with the hallucinogenic drug 
lysergic acid diethylamide (LSD) and antipsychotic drugs.  A marked reduction was 
found at 5-HT2C-VGV receptors in the efficacy of LSD and antipsychotics, suggesting a 
possible role for editing in the etiology and treatment of schizophrenia.  Initial studies of 
antipsychotic drugs suggested that a reduction in the constitutive activity of the non-
edited INI isoform differentiated atypical from typical antipsychotics (Herrick-Davis et 
al., 1999; Niswender et al., 1999); however, a more recent study failed to confirm this 
difference (Rauser et al., 2001).  Niswender et al. (2001) examined the isoform 
distribution in human post-mortem brain tissue of normal controls and found the VSV 
variant to be the most abundant isoform.  They also examined total RNA from the 
prefrontal cortex (PFC) (Brodmann areas 8 and 9) of 13 controls, 13 major depressed, 
and 13 schizophrenic subjects and found no significant differences in editing between the 
groups.  However, upon analyzing suicide versus non-suicide, the suicide population 
exhibited significantly higher levels of editing at the A-site, independent of diagnosis.  
On the other hand, a study by Sodhi et al. (2001) found that RNA editing frequencies in 
the PFC (Brodmann area 46) of schizophrenics was reduced at all editing sites, but only 
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editing at the B-site reached statistical significance.  Consequently, this association was 
found with only five schizophrenic patients and was largely due to the INI isoform which 
was found at 20% in the schizophrenics and not at all in the controls.   
A more recent study has shown that depressed suicide victims have alterations in 
RNA editing (Gurevich et al., 2002a).  Gurevich et al. examined the dorsal PFC 
(Brodmann area 9) of 5 controls and 6 matched suicide victims (5 of which were 
diagnosed with a depressive illness).  Only one of the suicide victims had a history of 
antidepressant and neuroleptic drug treatment prior to death.  Upon comparison of the 
two groups, there was a significant increase in editing of the C´-site (also known as the E-
site) and a significant decrease in editing of the D-site in the depressed suicide victims.  
There was also a trend for increased editing at the C-site.  Furthermore, the suicide victim 
with a history of neuroleptic and antidepressant treatment prior to death differed from 
both controls and the other five suicide victims, mainly due to the high percentage of the 
non-edited INI isoform.  Iwamoto and Kato (2003) examined the RNA editing 
efficiencies of the A and D-sites of the 5-HT2C receptor mRNA in the PFC (Brodmann 
area 10) of patients with bipolar disorder (n=12), schizophrenia (n=13), major depressive 
disorder (n=11) and control subjects (n=15).  The authors did not find significant 
alterations in the editing efficiencies at these sites, but there was a trend for increased 
editing at the D-site in depressed patients and increased editing at the A-site in suicide 
victims.  Although not significant, this increased in editing efficiency of the A-site 
supports the results of Niswender et al. (2001).  Shortly after Iwamoto and Kato’s report 
came a study which investigated alternative splicing and RNA editing in the PFC 
(Brodmann area 46) of 15 schizophrenic patients and 15 controls.  No significant 
40 
differences in RNA editing efficiencies or alternative splicing were found confirming 
Niswender et al. (2001) results that RNA editing is not altered in schizophrenia.  Recent 
evidence suggests that 5-HT2C receptor editing is modulated by changes in 5-HT 
neurotransmission such as 5-HT depletion and treatment with agonists and antagonists 
(Gurevich et al., 2002b).   
Clearly, there is still a debate as to whether on not RNA editing of the 5-HT2C 
receptor is altered in psychiatric disorders.  Additional studies are needed with larger 
numbers of patient samples to give the groups more power to find a significant difference 
between the patient and control groups.  The inability of these groups to replicate each 
other’s findings could also be due to the different regions of the PFC analyzed or 
differences in the way brains were stored.  Although preliminary, Gurevich et al.’s 
(2002a) findings in the one suicide victim with a history of drug treatment lends support 
to the hypothesis that drug treatment may alter RNA editing.  This serves as another 
potential problem when trying to replicate these findings since various drugs may affect 
RNA editing of the 5-HT2C receptor differently.  These findings lend further support to 
the hypothesis that RNA editing is an important process that regulates synaptic input in 
certain brain areas by fine tuning optimal signaling.  This in turn may lead to novel drug 
treatments for psychotic patients.     
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Genetics of 5-HT2C Receptors 
 
Single Nucleotide Polymorphisms 
Single nucleotide polymorphisms (SNPs) are substitutions of the wild-type 
nucleotide for a novel nucleotide within the genomic DNA.  SNPs are the most common 
type of genetic variation and occur at a frequency greater than 1% (Wang et al., 1998).  
Within the coding region of a gene, SNPs that cause a change in the encoded amino acid 
(non-synonymous SNP) may have a deleterious consequence on protein folding.  Many 
such polymorphisms produce an unstable conformation of the protein, resulting in 
retention in the endoplasmic reticulum and decreased plasma membrane expression 
(Wenkert et al., 1996).  Non-synonymous SNPs can also interfere with plasma membrane 
retention mechanisms, such as palmitoylation and glycosylation.  Finally, alterations in 
the amino acid structure can have dramatic consequences on the function of a protein.  
SNPs that alter the primary protein structure of a G-protein coupled receptor could 
modify the binding pocket of the receptor, disrupting receptor-ligand interactions, and 
thus changing the binding properties of the drug or the ability of the receptor to isomerize 
to the active form.  Alternatively, non-synonymous SNPs may interfere with the G-
protein coupling region of the receptor, changing the kinetics of receptor-G-protein 
interaction in either the ligand-activated or basal state of the receptor.  SNPs in this 
region could also alter phosphorylation of the receptor or the binding of accessory 
scaffolding proteins necessary for internalization and desensitization of the receptor.  
Each of these problems would result in a diminished signal downstream of the receptor 
leading to altered, and possibly inappropriate, cellular response to stimuli.  
42 
Other forms of variation include coding polymorphisms that do not alter the 
amino acid sequence (silent or synonymous), promoter polymorphisms and variable 
number of tandem repeat (VNTRs) in 5' and 3' untranslated regions (UTRs).  However, 
the consequences of these polymorphisms have been more difficult to deduce.  Each of 
these types of SNPs may have an indirect impact on receptor expression by altering the 
efficiency of transcription or translation.  Diminished or enhanced receptor expression 
will impact the signaling cascade downstream of neurotransmitter, thus altering the 
overall cellular response to the stimulus. 
Most polymorphisms are synonymous or non-coding in nature.  This is believed 
to occur because there is selection against non-synonymous polymorphisms in most 
genes due to the high likelihood of deleterious effect on protein structure and function. 
SNP frequency is also known to vary by race (Jorde, 2001; Tishkoff, 2002) and by 
gender.  The frequency of SNPs can vary tremendously between populations, and there 
are many reports of enriched frequencies of SNPs in African populations (Alonso, 2001; 
Jorde, 2001).  This ethnic variability – diminished diversity in non-African populations – 
is consistent with a genetic bottleneck during migration out of Africa and should be 
carefully considered when choosing a population for association analysis. Gender is a 
factor for polymorphisms that occur on genes of the X- and Y-chromosomes. SNPs that 
occur in this region may have a dose-dependent effect in both males and females.  
Clearly, the single copy of the X- or Y-chromosome in men can impact the frequency at 
which these SNPs can occur among males.  Additionally, the X-chromosome also 
undergoes the phenomena of X-chromosome inactivation (XCI) – the silencing of one 
copy of the X-chromosome.  XCI will not change the genotypic frequency of a 
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polymorphism in females, but it can alter the phenotypic consequence of variability of the 
silenced gene.  By means similar to XCI, several autosomal genes are imprinted – an 
event wherein one or several genes on a chromosome are selectively inactivated in a 
tissue- or developmental-specific manner.  Polymorphisms that occur only in an 
imprinted gene may have no phenotypic or functional consequence upon the individual, 
yielding a greater degree of complexity to association studies.  Lastly, some genes are 
reported to be imprinted in a polymorphic manner, including the 5-HT2A receptor gene 
(Bunzel et al., 1998).  This indicates that the gene is silenced in some individuals but not 
in others, and selective inactivation may result from a SNP within the gene or the 
imprinting machinery. 
 
HTR2C Gene 
The HTR2C gene that encodes 5-HT2C receptor is X-linked (human chromosome 
Xq24; mouse chromosome X D-F4).  The HTR2C gene contains six exons and five 
introns spanning at least 230 kb of DNA.  However, the coding region of the 5-HT2C 
receptor contains three introns as opposed to two introns in the 5-HT2A and 5-HT2B 
receptors.  The complete cDNA consists of 4775 nucleotides of which 728 are in the 5´- 
untranslated region, 1377 in the coding region, and 2670 in the 3´-untranslated region 
encoding a protein of 458 amino acids with an estimated mass of 53 kDa (Xie et al., 
1996).  The 5´ leader region comprises exon I, II, and a small portion of exon III.  The 5-
HT2C receptor cDNA coding region extends from the rest of exon III to exon VI (Fig. 10).  
The 5´-untranslated region of the human receptor is 80% homologous to the rat sequence 
except for a sequence of 80 bases 5´ of the translation start site (Saltzman et al., 1991),  
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however there is controversy as to whether this region actually exists in the human 
receptor (Xie et al., 1996).  Overall, the human 5-HT2C receptor sequence is 90% 
homologous to the rat receptor.   
The human and rat 5-HT2C receptors are most divergent at the N-terminal 
extracellular domain (78% homology) and their third cytoplasmic loop (71% homology).  
However, there is a single conserved potential N-linked glycosylation site in the N-
terminus of both species (Fig. 11), which may play a role in trafficking of the receptors 
(Saltzman et al., 1991).  There are a total of six potential glycosylation sites in the mouse 
and rat 5-HT2C receptor (Yu et al., 1991) while there are four in the human (Saltzman et 
al., 1991). The mouse, rat, and human 5-HT2C receptors have greater than 80% sequence 
homology in their transmembrane domains.  The 5-HT2C receptor possesses an extra 
hydrophobic domain at its N-terminus that could serve as an extra transmembrane 
domain, but recent evidence suggests that this may not be the case (Hurley et al., 1999).  
There are eight serine/threonine residues in the rat 5-HT2C receptor which represent 
potential phosphorylation sites, and are conserved in the human receptor (Barnes and 
Sharp, 1999).  Two different RNA processing events, RNA splicing and RNA editing 
take place in the 5-HT2C RNA generating diversity through expression of different 
isoforms of the protein.   
 
Polymorphisms within the 5-HT2C Receptor Gene 
Overall sequence identity between the 5-HT2A and 5-HT2C receptors is ~50% 
across the entire receptor and approximately 80% in the transmembrane regions.  The 
serotonin 5-HT2C receptor gene lies on the X-chromosome at Xq24 and it contains three 
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                                                              I 
                                                                 60 
Mouse MVNLGTAVRSLLVHLIGLLVWQFDISISPVAAIVTDTFNSSDGGRLFQFPDGVQNWPALS 
Rat   MVNLGNAVRSLLMHLIGLLVWQFDISISPVAAIVTDTFNSSDGGRLFQFPDGVQNWPALS 
Human MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGR-FKFPDGVQNWPALS 
                                      
                                    II 
                                                                 120 
Mouse IVVIIIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYV 
Rat   IVVIIIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYV 
Human IVIIIIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYV 
                       
                        III                                  IV 
                                                                 180 
Mouse WPLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAVRSPVEHSRFNSRTKAIMKIAIVW 
Rat   WPLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAIRNPIEHSRFNSRTKAIMKIAIVW 
Human WPLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAIRNPIEHSRFNSRTKAIMKIAIVW 
 
                                                  V 
                                                                 240 
Mouse AISIGVSVPIPVIGLRDESKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYFLTIY 
Rat   AISIGVSVPIPVIGLRDESKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYFLTIY 
Human AISIGVSVPIPVIGLRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYCLTIY 
 
 
                                                                  300 
Mouse VLRRQTLMLLRGHTEEELRNISLNFLKCCCKKGDEEE-NAPNPNPDQ-KPRRKKKEKRPRG 
Rat   VLRRQTLMLLRGHTEEELANMSLNFLNCCCKKNGGEEENAPNPNPDQ-KPRRKKKEKRPRG 
Human VLRRQALMLLHGHT-EEPPGLSLDFL-KCCKRNTAEEENSANPNQDQNARRRKKKERRPRG 
 
                              VI                           VII 
                                                                 360 
Mouse TMQAINNEKKASKVLGIVFFVFLIMWCPFFITNILSVLCGKACNQKLMEKLLNVFVWIGY 
Rat   TMQAINNEKKASKVLGIVFFVFLIMWCPFFITNILSVLCGKACNQKLMEKLLNVFVWIGY 
Human TMQAINNERKASKVLGIVFFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGY 
 
 
                                                                 420 
Mouse VCSGINPLVYTLFNKIYRRAFSKYLRCDYKPDKKPPVRQIPRVAATALSGRELNVNIYRH 
Rat   VCSGINPLVYTLFNKIYRRAFSKYLRCDYKPDKKPPVRQIPRVAATALSGRELNVNIYRH 
Human VCSGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRH 
 
 
                                             460 
Mouse  TNERVVRKANDTEPGIEMQVENLELPVNPSNVVSERISSV 
Rat      TNERVARKANDPEPGIEMQVENLELPVNPSNVVSERISSV 
Human  TNEPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV 
 
Figure 11: 5-HT2C receptor species alignment.   
Alignment of the mouse, rat, and human 5-HT2C receptors.  Amino acids in blue 
represent a putative conserved glycosylation sequence.  Squared regions are regions of 
homology.  Lines represent putative transmembrane domains. 
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introns within the coding region which spans approximately 1.4 Kb.  Not only does the 5-
HT2C receptor achieve its diversity through molecular mechanisms such as RNA splicing 
and RNA editing, it also creates genetic diversity with the incorporation of SNPs.  To 
date, there are three reported SNPs and two dinucleotide repeats in the promoter region of 
this receptor and one SNP in the 3' untranslated region (Fig. 12; Table 2).  There have 
been two different reports of dinucleotide repeats in the promoter region of the 5-HT2C 
receptor (Yuan et al., 2000; Meyer et al., 1999).  Based upon the numbered locations of 
the repeats the two groups reported, it seems that there was three different dinucleotide 
repeats; two GT repeats and one CT repeat.  However, careful examination of the 
promoter sequence (Xie et al., 1996) reveals that the two GT repeats were one and the 
same. The differences in sequence number resulted from one group numbering from the 
translation initiation codon (exon 3) and the other from the first exon. The functional 
characteristics of the promoter SNPs in the 5-HT2C receptor have been examined in only 
two reports, both of which evaluated a series of alleles found at linked loci on a single 
chromosome know as haplotypes using luciferase reporter gene constructs (Yuan et al., 
2000; Meyer et al., 2002). Yuan’s group found that promoter activity of haplotype 2 (-
1,027(GT)11, -697C) and haplotype 3 (-1,027(GT)11, -995A, -759T, -697C) was 1.44 
and 2.58 fold higher than the wild type haplotype (-1,027(GT)17, -995G, -759C, -697C). 
Although there is not much functional data on these SNPs in the promoter of the 5-HT2C 
receptor, many groups have begun to examine them in disease association studies as 
summarized in Table 3. Of these, the most promising seems to be the -759C/T 
polymorphism. These haplotypes containing the nucleotide substitutions in the promoter 
have been associated with higher transcription levels and resistance to obesity and Type 
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Table 2: Frequency and distribution of 5-HT2C receptor SNPs. 
Nucleotide 
Substitution 
Nucleotide 
Position 
Amino Acid 
Substitution 
Domain Minor 
Allele 
Frequency 
Reference 
5-HT2C 
Receptor 
     
(CT)4-5 -963 - Proximal to 
NF-IL6 
binding site 
- Myer et al., 
1999 
(GT)n -1,027 - Between two 
NF-IL6 
binding sites 
Major: 
(GT)17 
Yuan et al., 
2000 
[G/A] -995 - Between two 
NF-IL6 
binding sites 
11% Yuan et al., 
2000 
[C/T] -759 - Proximal to 
LF-A1 
binding site 
11% Yuan et al., 
2000 
[G/C] -697 - Between -703 
and -692 
transcription 
initiation sites 
15% Yuan et al., 
2000 
 [G/C] 68 C23S NT 13% Lappalainen et 
al., 1995 
[T/G] 2831 - 3′ UTR 10% Song et al., 
1999 
[A/G] 1255 T419A CT <1% Gibson et al., 
2004 
[C/G] 10 L4V NT 1% dbSNP 
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II diabetes (Yuan et al., 2000).  All together, these studies support the hypothesis that 
SNPs in the promoter region of the 5-HT2C receptor may alter transcription levels of the 
protein, and could potentially change the neuronal regulation of food intake in the 
hypothalamus. Therefore, continued identification and characterization of polymorphisms 
in the promoter region of this receptor are important.  Two SNPs has been identified in 
the coding region of the 5-HT2C receptor, one converting a cysteine (Cys) to a serine 
(Ser) at amino acid codon 23 (Lappalainen et al., 1995) and the other converting a 
threonine (Thr) to an alanine (Ala) at amino acid codon 419 (Fig. 13; Gibson et al., 
2004).  The latter SNP was only found in one early onset obese patient and has not been 
confirmed.  Still another SNP found in the dbSNP database, converts a leucine (Leu) to a 
valine (Val) at amino acid condon 4.  This SNP has not been reported elsewhere.  Besides 
the present work, there have been only two functional studies performed on the Cys23Ser 
polymorphism.  The first was conducted by the group that originally discovered it. 
Recombinant human 5-HT2C-Cys and 5-HT2C-Ser receptors were expressed in frog oocytes 
and 5-HT’s ability to activate Ca2+ activated chloride channels evaluated (Lappalainen et 
al., 1995). Although no significant differences were found in this study, more detailed 
studies are needed to functionally characterize this variant in mammalian cell lines since 
so many association studies have found position correlations with the 5-HT2C-Ser allele 
(Table 3).  Therefore, our laboratory has embarked upon a thorough pharmacological 
characterization of the 5-HT2C-Ser receptor variant in both an edited and non-edited 
backbone.   
Numerous human studies have examined the association of the Cys23Ser SNP 
with disease states and drug responses (Table 3). One of the most frequently examined 
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Table 3: Association studies of SNPs in the human 5-HT2C receptor 
MDD: Major Depressive Disorder; SAD: Seasonal Affective Disorder; Sp.-Clz response: Schizophrenia-Clozapine response; 
Sp./TD: Schizophrenia and/or Tardive Dyskinesia; BD: Bipolar Disorder; WG/ED: Weight Gain/Eating Disorder; AD: 
Alzheimer’s Disease; Alc: Alcoholism; Neg: negative association; Pos: positive association; Mix: reports of positive and negative 
association; N/A: not studied.  
 
SNP MDD Suicide SAD Sp.-Clz 
response 
Sp./TD BD WG/ED AD Alc 
5-HT2C 
Receptor 
         
(GT)12-
18/ (CT)4-
5 
N/A N/A N/A Pos.23 N/A Neg.22 Pos.12 N/A N/A 
-759C/T N/A N/A N/A Neg.
27 Mix. 
9,26,32 
N/A Mix.12,13,29 N/A N/A 
-697G/C N/A N/A N/A N/A Pos.9,32 N/A Pos.12 N/A N/A 
C23S Mix.
1,2,21 Neg.24,25 Neg.4 Mix.5,6,7 Pos.8 Mix.2,10,11,21 Mix. 
14,15,16,28 
Mix. 
17,19,30 
Mix.18,20,31 
 
References (superscript) 1: Frisch et al.,  1999; 2: Lerer et al.,  2001; 4: Johansson et al.,  2001; 5: Malhotra et al.,  1996; 6: Sodhi et al.,  1995; 7: Masellis et 
al.,  1998; 8: Segman et al.,  2000; 9: Zhang et al.,  2002; 10: Gutierrez et al.,  1996; 11: Oruc et al.,  1997; 12: Yuan et al.,  2000; 13: Reynolds et al.,  2002; 
14: Westberg et al.,  2002; 15: Burnet et al.,  1999; 16: Lentes et al.,  1997; 17: Holmes et al.,  1998; 18: Himei et al.,  2000; 19: Holmes et al.,  2003; 20: 
Hill et al.,  2002; 21: Serretti et al.,  2000 ; 22: Gutierrez et al.,  2001; 23 Arranz et al.,  2000; 24: Stefulj et al.,  2004; 25: Pooley et al.,  2003; 26: Ellingrod 
et al.,  2004; 27: Theisen et al.,  2004; 28: Hu et al.,  2003; 29: Pooley et al.,  2004; 30: Assal et al 2004; 31: Johann et al.,  2003; 32: Reynolds et al.,  2003 
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phenotypes is clozapine response in schizophrenic patients; both positive and negative 
results have been reported with more evidence leaning towards a lack of association.  The 
Cys23Ser polymorphism has also been shown to be associated with visual hallucinations 
and hyperphagia in Alzheimer’s patients (Holmes et al., 1998); however, this finding has 
not been confirmed.  Moreover, association studies of 5-HT2C receptor polymorphisms 
require extra care since the gene is on the X chromosome.  Some groups fail to address 
this issue although many have begun to analyze males and females separately.  
 
Consequences of Genetic Variation 
It has recently been hypothesized that common genetic variation may significantly 
contribute to risk for common diseases – the common disease-common variant (CD-CV) 
hypothesis (Cargill, 1999).  If this hypothesis is accurate, then normal genetic variation 
within serotonin receptors could increase the likelihood of developing a psychiatric 
disorder linked to serotonergic pathways, such as depression or schizophrenia.  Thus far, 
much of the association data that have been generated for SNPs in the 5-HT2A/2C receptor 
genes have been inconclusive.  Often times a larger sample size would address many of 
the problems with these association studies.  However, many of the disease states that 
could be impacted by the serotonergic system are polygenic in nature and are further 
influenced by environmental factors.  This necessitates a large, well-defined disease 
population with several sub-phenotypes that can each be specifically evaluated with 
respect to the disease of interest.  It is only by thorough investigation of the intricacies of 
these diseases that we will uncover the role that 5-HT2A/2C receptor polymorphisms may 
play in complex polygenic disorders.  Finally, although functional investigations of the 
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promoter and non-synonymous SNPs of the 5-HT2A/2C receptors have been initiated, there 
is still a need for a deeper investigation into the consequence of these polymorphisms.  
Studies are currently underway to further clarify the impact of these polymorphisms on 
the structure and function of the human 5-HT2A/2C receptors.  Additional understanding of 
the consequence of these SNPs will provide greater insight into the role of the serotonin 
5-HT2A/2C receptors in complex human diseases, and may help define unique populations 
and sub-phenotypes for future association studies. 
 
Specific Aims 
Since the original discovery of the Cys23Ser polymorphism in the human 5-HT2C 
receptor, little work has been done to look at the structural and functional consequences 
of this amino acid substitution.  On the other hand, there have been numerous association 
studies in human subjects trying to link the polymorphism to various disease states, 
including major depressive disorder.  The Cys23Ser polymorphism has been shown to 
associate with individuals who have late onset Alzheimer’s disease with visual 
hallucinations and hyperphagia (Holmes et al., 1998), in addition to schizophrenia 
patients with tardive diskinesia (Segman et al., 2000).  Recently, a genetic component of 
unipolar depression was identified (Sullivan et al., 2000).  There have been only two 
association analyses of the Cys23Ser SNP with unipolar depression.  One of these 
studies, performed on a population of European subjects found a positive association 
between the occurrence of the Ser23 allele with unipolar depression and bipolar disorder 
(Lerer et al., 2001).  Such studies are driven by the emerging pharmacological evidence 
that the 5-HT2C receptor may be involved in depression.  For example, in studies of the 
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rat forced swim test, three novel selective 5-HT2C receptor agonists, WAY 161503, RO 
60-0175, and RO 60-0332, all decreased immobility and increased swimming, a pattern 
of behavior similar to that produced by the selective serotonin reuptake inhibitor (SSRI) 
fluoxetine.  Furthermore, the selective 5-HT2C receptor antagonist SB 206553 blocked the 
antidepressant-like effects of both WAY 161503 as well as fluoxetine (Cryan and Lucki, 
2000), suggesting a role for 5-HT2C receptors in the behavioral effects of antidepressant 
drugs.    
Depression is a complex disease, making it highly unlikely that one SNP could 
cause all forms of unipolar depression.  On the other hand, it is plausible that the 
Cys23Ser polymorphism in the 5-HT2C receptor could cause an endophenotype of 
depression such as anxiety.  The fact that this polymorphism occurs at a relatively high 
percentage (13%), suggests that this variation could have a functional consequence and 
thereby be of physiological relevance.  The goal of this project is to determine the 
functional impact of the Cys23Ser SNP in mammalian cells and to examine its 
occurrence in selected patient populations.   
In order to reach these goals, I have developed several specific aims.  My first aim 
was to generate and express edited and non-edited polymorphic human 5-HT2C receptors.  
Polymorphic receptors were created using PCR site-directed mutagenesis and were then 
transfected into cells to create cell lines that express the variant receptors.  My next aim 
was to examine the functional impact of the Cys23Ser SNP on the human 5-HT2C 
receptor.  This involved performing radioligand binding using various ligands to 
determine receptor densities and to examine changes in affinity and conducting 
phosphoinositide hydrolysis to determine the EC50 and maximal effect after agonist 
56 
stimulation.  In order to investigate alterations in the expression patterns of these variant 
receptors, imunocytochemistry and surface biotinylation in combination with Western 
blot analysis was used.  The third and final aim was to elucidate the association between 
the Cys23Ser polymorphism and subpopulations of depressed patients.  First I identified 
subjects homozygous or heterozygous for the polymorphism within populations of 
depressed patients and control patients by genotyping DNA samples.  Then I analyzed the 
associations of the polymorphism with an endophenotype of depression by using 
statistical analyses with STATA software. 
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CHAPTER II 
 
PHARMACOLOGICAL PROPERTIES OF THE CYS23SER SINGLE 
NUCLEOTIDE POLYMORPHISM IN HUMAN 5-HT2C RECEPTOR ISOFORMS 
 
Introduction 
The serotonin 2C (5-HT2C) receptor is a seven transmembrane G-protein-coupled 
receptor (GPCR) that has only been found in the brain, where it is widely expressed 
(Mengod et al., 1990).  Upon activation through interactions with the heterotrimeric G-
protein, Gq (Chang et al., 2000), the 5-HT2C receptor leads to activation of phospholipase 
C (PLC), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol 
(DAG) and inositol 1,4,5-triphosphate (IP3).  Several mechanisms exist for the generation 
of molecular diversity in the 5-HT2C receptor, one of which is RNA editing.  RNA editing 
is a post-transcriptional event in which the coding potential of primary RNA transcripts is 
changed by mechanisms other than splicing.  The human 5-HT2C receptor mRNA 
undergoes A-to-I editing at five positions, generating multiple protein isoforms with 
different distributions and signaling capabilities (Niswender et al., 1999).  The human 5-
HT2C receptor edited isoforms, which have VSV or VGV at positions 156, 158, and 160 
have been shown to cause a decrease in agonist potency (Burns et al., 1997; Niswender et 
al., 1999; Fitzgerald et al., 1999) and constitutive activity (Niswender et al., 1999; 
Herrick-Davis et al., 1999), as well as altered patterns of G-protein coupling (Price et al., 
2001), suggesting that this editing process may be used to regulate signaling tone in the 
brain.   
58 
Another mechanism for creating diversity is at the genetic level.  A growing 
hypothesis is that common genetic variations may contribute significantly to the genetic 
risk for common disease (Lander, 1996).  The most common type of genetic variation is 
the single nucleotide polymorphism (SNP) (frequency > 1%; Wang et al., 1998), which 
occurs in the coding or non-coding region of the gene.  SNPs may change the amino acid 
coding potential of a GPCR which could interfere with protein folding, ligand binding, 
interactions with G-proteins and post-translational modifications of the protein (for 
review see Rana et al., 2001).  Since serotonin has been implicated in a variety of 
behavioral and neurochemical responses, genetic variations within the 5-HT2C receptor 
may increase the likelihood of the development of psychiatric disorders such as 
depression, anxiety, and schizophrenia.  In the coding region of the 5-HT2C receptor, a 
cysteine (C) to serine (S) change has been identified at the 23rd amino acid (C23S) 
(Lappalainen et al., 1995).  The 5-HT2C receptor C23S polymorphism has been shown to 
associate with many disease states.  One such disease is schizophrenia, in which the C23S 
SNP has been shown to associate with a positive response to the atypical antipsychotic 
drug clozapine (Sodhi et al., 1995) and tardive diskinesia (Segman et al., 2001).  Bipolar 
disorder, major depression (Lerer et al., 2001), and hallucinations in Alzheimer’s disease 
(Holmes et al., 1998) have also been positively associated with this polymorphism.  
Given that this genetic variation has been associated with numerous diseases implies that 
this SNP may have an actual functional consequence on the protein which may increase 
the likelihood of a disease.  It is therefore important to examine the function of the 
polymorphic variant.  Furthermore, since the edited VSV isoform is the principal 5-HT2C 
receptor isoform found in the human brain, it is necessary to determine the properties of 
59 
the C23S SNP in this edited background.  Therefore, the purpose of this study was to 
examine the functional impact of the C23S polymorphism on the 5-HT2C receptor in non-
edited and edited VSV receptors expressed in three different mammalian cell lines. 
 
Materials and Methods 
 
Site-directed mutagenesis   
Human 5-HT2C receptor variants were prepared by PCR site-directed 
mutagenesis.  PCR amplification was executed with two primer sets in two rounds.  The 
first round consisted of the following primers: 1) 5′-CACCCCAGGCTTTACACTTTAT-
3′ and 2) 3′-AACCAAACCGTTAGACTATAGAGACACTCGGGT-5′. Round two 
consisted of the following primers:  1) 5′-CACCCCAGGCTTTACACTTTAT-3′ and 2) 
5′-ACAGGCCTTCCCACAAAGAACAGACAGAATATTGG-3′.  Each set consisted of 
a primer containing the SNP and a flanking primer.  The expression vector Bluescript 
(Stratagene, La Jolla, CA) containing wild-type human 5-HT2C receptor (INI or VSV) 
served as the template.  Once amplified by recombinant Pfu polymerase (Promega, 
Madison, WI), the mutated region was cut with the restriction enzymes EcoR I and Avr II 
and ligated into wild-type cDNA to generate the full-length expression construct.  S23 
receptors were verified by restriction digests and ABI 310 automated DNA sequencing.  
The entire receptor sequence containing the S23 SNP was cut out with EcoR I and Xba I 
and ligated into the mammalian expression vector pCMV2 (a gift of Dr. David Russell). 
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Expression and Cell Culture   
In order to make stable cell lines, NIH-3T3 fibroblasts were transfected by co-
electroporation of pCMV2 containing C23 or S23 5-HT2C-INI or 5-HT2C-VSV receptor 
cDNA and empty pcDNA3 plasmid (0.3 µg; Invitrogen, Carlsbad, CA) using the Bio-Rad 
Gene Pulser II.  Cells with the receptor were initially selected in Dulbecco’s modified 
eagle medium (DMEM, GIBCO, Grand Island, NY) supplemented with 10% bovine calf 
serum (Hyclone Laboratories, Logan, UT), antibiotics (5 units/ml penicillin and 5 µg/ml 
streptomycin; Life Technologies, Inc.), and 2 mg/ml G418 (Geneticin, Life Technologies, 
Inc.).  The concentration of G418 was then gradually decreased to 0.5 mg/ml and stable 
cell lines were maintained in this medium at 37°C with 5% CO2.  For transient expression 
in NIH-3T3 fibroblasts and COS-7 cells, cells were plated in 12 or 24 well, or 100 mm 
plates 24 hours prior to transfection.  Both cells types were transfected by combining 
Fugene 6 reagent (Roche Diagnostics Corporation, Indianapolis, IN) and (0.25-1 µg) 
plasmid in serum free DMEM according to manufacturer’s instructions.  HEK293 cells 
(4x106 cells/100 mm dish) were transfected with 1 µg 5-HT2C-INI using Lipofectamine 
Reagent (Life Technologies, Inc.) and replated in 24 well plates at 2x105 cells/well.  
 
Human 5-HT2C Receptor Antibody   
In order to generate antibodies to the human 5-HT2C receptor, peptides were 
directed against the C-terminus of the receptor as previously described (Backstrom et al., 
1997).  Rabbits were immunized with constructs containing the human 2C-CT peptide 
and purified using two columns. Serum was passed through a column containing the rat 
2C-CT peptide and the flow-through applied to a second column containing the human 
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2C-CT peptide. Thus, the anti-human antibodies have considerably higher reactivity 
against human receptors relative to rat receptors. 
 
Fluorescence microscopy   
HEK293 cells (2x106 cells) were transfected with 0.1 µg of C23 or S23 5-HT2C-
INI/YFP cDNA.  Twenty-four hours post transfection, the cells were replated on poly-D-
lysine-coated coverslips in MEM (with serum) and incubated overnight prior to imaging. 
The cells were washed in PBS and viewed live using a Zeiss LSM 510 Meta Confocal 
Imaging System.  
 
Surface Biotinylation and western blotting   
For each receptor variant, one 100 mm plate of NIH-3T3 stable cell line was 
serum starved 16 hours prior to assay.  After aspiration of medium, the plates were 
washed 3 times with cold Hank’s balanced salt solution (HBSS).  Sulfo-NHS-SS-Biotin 
in HBSS (1mg/mL; Pierce, Rockford, IL) was added (total volume=2 ml) and incubated 
at 4°C for 20 minutes while rocking.  The biotin solution was aspirated and 2 ml of fresh 
biotin solution (1 mg/ml) was added for an additional 20 minutes at 4°C.  After aspiration 
of the biotin solution, cells were washed three times with cold HBSS and scraped into 
phosphate-EDTA buffer (PE; 0.04 M NaH2PO4, 0.01 M Na2HPO4, 0.01 M disodium 
EDTA, 0.002 M EGTA, pH 7.2) with 0.5 µg/ml leupeptin and 100 µM PMSF.  Cell were 
then sonicated for 5 seconds and centrifuged at 16000xg for 10 minutes. Pellets were 
resuspended in 1mL PE-CHAPS (PE plus 0.01 M CHAPS) with 0.5 µg/ml leupeptin and 
100 µM PMSF, sonicated for 5 seconds, and incubated on ice for 30 minutes.  Samples 
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were then centrifuged at 16000xg for 10 minutes at 4°C and the BCA protein assay 
(Pierce) performed on the supernatants.  After dilution to equal protein concentrations, 30 
µl aliquots of each sample were set aside for future western analyses.  The remainder of 
the sample was added to 100 µl of immobilized streptavidin beads (Pierce) and rocked at 
4ºC for 1 hour.  Streptavidin-biotin complexes were separated by centrifugation at 
16000xg for 2 minutes and washed 3 times with 1 ml of PE-CHAPs buffer.  Biotinylated 
proteins were eluted from the complex by adding sample buffer containing 50 mM DTT 
and incubating at 50ºC for 40 minutes.  Samples were resolved on a 10% SDS-PAGE 
precast minigels (Cambrex Bio Science, Rockland, ME) and proteins transferred to 
nitrocellulose.  Nitrocellulose membranes were washed and blocked by incubation in 3% 
BSA for 1 hour and subsequently incubated with a primary antibody directed against the 
C-terminus of the human 5-HT2C receptor (2 µg/ml) for 1.5 hours. After washing 3 times, 
the membranes were incubated with alkaline-phosphatase conjugated goat-anti-rabbit 
secondary antibody (1:1000; Dako, Carpinteria, CA) for 1 hour.  Receptor protein was 
detected with nitro-blue tetrazolium chloride (NBT) and 5-bromo-4-chloro-3’-
indolyphosphate (BCIP) (Pierce) in buffer (100 mM Tris, 100mM NaCl, 5 mM MgCl2, 
pH 9.5). 
 
Quantification of immunoblots   
Protein band densities were scanned on an Epson Expression 636 scanner and 
quantified using the public domain Image J program developed at the National Institutes 
of Health.  Graphs represent the mean optical density from three different experiments.  
Student’s t test (two-tailed) was used to compare the means of the band densities. 
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Radioligand Binding  
Membranes were prepared after washing cells with Hank’s balanced salt solution 
(HBSS) (+Ca2+/Mg2+).  Ice-cold binding buffer (50 mM Tris, 10 mM MgCl2, pH 7.4,) 
was added and cells were scraped off plates and placed in ultracentrifuge tubes.  After 
brief homogenization (2 seconds with a Polytron), the membranes were spun at 20,000g 
for 20 minutes at 4°C.  The pellet was resuspended in binding buffer and protein 
concentrations were determined with the BioRad protein assay.  For saturation 
experiments, 500 µl (50 µg) of membrane preparation, 50 µl of 50 mM Tris buffer, and 
50 µl of varied concentrations [N6-methyl-3H]-mesulergine (Amersham Pharmacia 
Biotech, UK) were mixed together and incubated at 37°C for 30 minutes.  Competition 
binding was carried out on membranes prepared as described above and incubated with 
1nM [3H]-mesulergine and varying concentrations of competitor.  Nonspecific binding 
was determined with 10 µM methysergide.  Following incubation, free drug was 
separated from bound drug by vacuum filtration onto Whatman GF/C glass filters 
(Brandel, Gaithersburg, MD).  The filters were placed in scintillation vials and counted 
on a Packard Tri-Carb scintillation counter (Packard Instrument Company, Downers 
Grove, IL).  Bmax and KD values were determined from saturation isotherms using 
GraphPad Prism (GraphPad Software, Inc., San Diego, CA).  In some competition 
binding experiments, 100 µM guanosine 5'-(β,γ-imido)triphosphate [Gpp(NH)p] was 
added to shift all receptors to the low affinity state.  IC50 values were determined by 
fitting data to a sigmoidal curve with variable slope using GraphPad Prism; one-site and 
two-site binding curves were compared using the F ratio.  IC50 values were converted to 
Ki values using the transformation of Cheng-Prusoff (1973). 
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Phosphoinositide (PI) Hydrolysis   
For transients, 24 hours post transfection cells were washed and then incubated 
for 16-20 hours in serum-free, inositol-free DMEM with 1 µCi myo-[3H]inositol/ml (20-
25 Ci/mmol, NEN Life Science Products).  The experiment was initiated after adding 10 
mM lithium chloride and 10 µM pargyline and incubating for 15 minutes at 37ºC.  
Agonist (either 5-HT or DOI) was added and plates were incubated for an additional 30 
minutes at 37°C.  The reaction was stopped by aspirating the medium and fixing the cells 
with 50 µl of methanol per well.  [3H]-inositol monophosphates were isolated as 
previously described (Barker et al., 1994).  The data were analyzed with GraphPad Prism 
3.0 software to determine maximum responses and EC50 values. 
 
Fluorescence Resonance Energy Transfer (FRET)   
HEK293 cells (4 x 106 cells/100mm dish) were co-transfected with 0.2ug of 5-
HT2C-INI/CFP (donor) and 0.4 µg of 5-HT2C-INI/YFP (acceptor) using 20 µl of 
lipofectamine. Twenty-four hours post transfection, cells were plated in serum-free media 
on poly-lysine coated glass cover slips for 16 hours prior to the FRET assay.  The cells 
were viewed live in phosphate buffered saline using a Zeiss LSM-510 META confocal 
imaging system with a 30 mW argon laser and 63x 1.4 NA oil immersion objective.  
FRET was measured by acceptor photobleaching (Bastiaens et al., 1996) using linear 
unmixing of CFP and YFP emission spectra as previously described.20  Briefly, confocal 
microscopy was used to isolate a 2µm thick optical section through the middle of a live 
cell expressing both 5-HT2C-INI/CFP and 5-HT2C-INI/YFP.  A prebleach image was 
captured using an argon laser with a 458 nm/514 nm dual dichroic.  A region of the 
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plasma membrane was scanned with the 514 nm laser (100% intensity) for 30 seconds to 
photobleach YFP, and postbleach images were captured.  FRET was measured as an 
increase in CFP fluorescence intensity (donor de-quenching) following YFP 
photobleaching.  FRET efficiency was calculated as follows: 100 x (CFP postbleach - 
CFP prebleach) / CFP postbleach.  Donor/acceptor ratios were calculated as donor 
fluorescence divided by acceptor fluorescence, measured prior to photobleaching.  FRET 
efficiencies measured in 10 cells transfected with 5-HT2C-INI/CFP alone ranged from -
3.6% to +2.9%, with an average of 0.3%. Similar results were obtained from non-
bleached regions of the plasma membrane. 
 
Results 
 
Cellular distribution of C23 and S23 5-HT2C receptors are similar   
Many GPCR SNPs cause improper folding of proteins, leading to retention in the 
ER or Golgi and reduced receptor at the cell surface (for recent review, see Bernier et al., 
2004).  In order to examine the impact of the C23S polymorphism on protein localization, 
HEK293 cells were transiently transfected with C23 or S23 5-HT2C-INI/YFP cDNA and 
subjected to confocal imaging.  C23 and S23 5-HT2C-INI receptors showed similar 
fluorescence patterns with intense plasma membrane labeling and some intracellular 
fluorescence (Fig. 14).  A more quantitative estimate of receptor expression on the 
plasma membrane was obtained using surface biotinylation of NIH-3T3 fibroblasts stably 
expressing C23 or S23 5-HT2C-INI or 5-HT2C-VSV receptors.  The amount of surface 
biotinylated 5-HT2C receptor was not significantly different between cells expressing C23  
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Figure 14: Cellular distribution of C23 5-HT2C-INI and S23 5-HT2C-INI receptors 
HEK293 cells were transfected with 0.1µg of C23 or S23 5-HT2C-INI/YFP cDNA.  
Twenty-fours hours post transfection, the cells were re-plated on poly-D-lysine-coated 
coverslips in MEM (with serum) overnight prior to imaging.  The cells were washed in 
PBS and viewed live using a Zeiss LSM 510 Meta Confocal Imaging System. DIC: 
differential interference contrast. 
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or S23 5-HT2C-INI or 5-HT2C-VSV receptor isoforms (Fig. 15 and 16), suggesting no 
difference in protein targeting to the cell surface.  All receptor isoforms migrated as 
broad bands with similar patterns between 40-68 kDa (Figure 15), agreeing with previous 
studies that the 5-HT2C receptor is glycosylated (Backstrom et al., 1995) and suggesting 
that the CS23S SNP does not alter the degree of glycosylation.   
 
High affinity binding is retained at S23 receptors   
NIH-3T3 fibroblasts were stably transfected with 5-HT2C-INI or 5-HT2C-VSV receptor 
cDNAs with or without the C23S polymorphism.  Competition binding was performed 
with [3H]-mesulergine to determine the affinity of agonists and antagonists at the variant 
5-HT2C receptors.  All of the ligands tested had similar affinity for C23 and S23 receptor 
variants (Table 4).  However, the competition binding curves were shallow both at C23 
and S23 5-HT2C-VSV receptors, as illustrated in Figures 17 and 18, for the hallucinogenic 
agonist (±)-1-(2,5-dimethoxy-4-phenyl)-2-aminopropane (DOI), suggesting multiple 
affinity states of the receptors.  The C23 5-HT2C-VSV receptor curve was best fit by a two 
site model with the high affinity state having a Ki of 0.73 ± 0.43 nM.  The addition of the 
GTP analog Gpp(NH)p shifted the competition curve to a single, low affinity state with a 
Ki of 40.3 ± 7.3 nM (Fig. 17).  The S23 5-HT2C-VSV receptor curve was also best fit by a 
two site model with the high affinity state having a Ki of 1.17 ± 0.63 nM.  Addition of 
Gpp(NH)p shifted the competition curve to a single, low affinity state with a Ki of 42.3 ± 
2.6 nM (Fig. 18).  The portion of high affinity agonist binding was equal for the C23 and 
S23 receptors (Table 5).  Similar results were observed with the agonists 5-HT and m-
chlorophenylpiperazine (m-CPP), but not lysergic acid diethylamide (LSD) (Table 5). 
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Figure 15: Surface biotinylation of C23 and S23 5-HT2C receptors and Western 
blotting  
NIH-3T3 fibroblasts stably expressing C23 5-HT2C-INI (Bmax 2.1 ± 0.2 pmol/mg), C23 5-
HT2C-VSV (Bmax 2.5 ± 0.3 pmol/mg), S23 5-HT2C-INI (Bmax 3.0 ± 0.3 pmol/mg), or S23 5-
HT2C-VSV (Bmax 2.2 ± 0.2 pmol/mg) receptors were labeled with biotin, extracted with 
streptavidin beads, and blotted with a polyclonal 5-HT2C receptor antibody as described 
in Materials and Methods.  Blot shown is a representative experiment that was replicated 
in three independent experiments.   
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Figure 16: Quantification of biotinylated 5-HT2C receptors 
Protein bands from three independent cell surface biotinylation experiments were 
quantified.  Results are expressed as percentages ± S.E.M. of WT (either C23 5-HT2C-INI 
or C23 5-HT2C- VSV) receptor band density for each protein species.  There was no 
significant difference in band densities from total cell lysates.  Optical density was 
measured for each band using Image J software as described in Materials and Methods.  
3T3: untransfected parental NIH-3T3 fibroblasts. 
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Table 4: Relative affinities for agonists and antagonists for C23 5-HT2C-VSV and S23 
5-HT2C-VSV receptors 
Ki values for the ligands were determined by competition for 1 nM [3H]-mesulergine in 
NIH-3T3 fibroblasts stably expressing C23 or S23 5-HT2C-VSV receptors.  Ki values are in 
nM and were determined using the method of Cheng and Prusoff.  Agonist competition 
curves were determined in the presence of 100 µM Gpp(NH)p.  Data represent the mean 
± S.E.M. of 3-8 independent experiments performed in duplicate. 
 
Agonist C23 S23 
5-HT 89 ± 9 97 ± 18 
DOI 41 ± 17 40 ± 3 
LSD 5.3 ± 0.96 6.5 ± 1.3 
mCPP 138 ± 60 150 ± 65 
Antagonist   
Clozapine 13.4 ± 4 18.2 ± 2 
Mianserin 2.87 ± 1.4 2.38 ± 1.2 
Fluoxetine 228 ± 98 190 ± 56 
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Figure 17: Competition binding of DOI for [3H]-mesulergine labeled C23 5-HT2C-VSV 
receptors 
DOI competition for 1 nM [3H]-mesulergine binding was measured in membranes 
prepared from NIH-3T3 fibroblasts stably transfected with C23 5-HT2C-VSV receptors in 
the presence (open circles) and absence (closed circles) of Gpp(NH)p.  The receptor 
density was1.5 ± 0.09 pmol/mg protein. 
72 
 
 
 
 
 
 
Figure 18: Competition binding of DOI for [3H]-mesulergine labeled S23 5-HT2C-VSV 
receptors  
DOI competition for 1 nM [3H]-mesulergine binding was measured in membranes 
prepared from NIH-3T3 fibroblasts stably transfected with S23 5-HT2C-VSV receptors in 
the presence (open squares) and absence (closed squares) of Gpp(NH)p.  The receptor 
density was 1.5 ± 0.08 pmol/mg protein. 
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Table 5: High and low affinities for agonists at C23 and S23 5-HT2C-VSV receptors 
Ki values for agonists were determined by competition for 1 nM [3H]-mesulergine in 
NIH-3T3 fibroblasts stably expressing C23 or S23 5-HT2C-VSV receptors.  Ki values are in 
nM and were determined using the method of Cheng and Prusoff.  Competition curves 
were in the absence of Gpp(NH)p and were best fit by a two site model.  Percentage of 
agonist in the high affinity state was calculated by GraphPad Prism. Data represent the 
mean ± S.E.M. of four independent experiments. 
 
High Affinity (KiH) % High Affinity Low Affinity (KiL) Agonist 
C23 S23 C23 S23 C23 S23 
5-HT 1.1 ± 0.3 1.7 ± 0.7 38 ± 4 42 ± 3 107 ± 14 154 ± 32 
DOI 0.6 ± 0.4 5.3 ± 4.2 19 ± 1 17 ± 1 68 ± 17 120 ± 55 
m-CPP 0.8 ± 0.3 0.8 ± 0.2 24 ± 2 23 ± 3 138 ± 25 150 ± 27 
 
74 
G-protein coupling and receptor signaling are comparable between C23 and S23 receptor 
variants 
 
The 5-HT2C receptor has been shown to interact with G-proteins and activate 
intracellular signaling in the absence of agonist, an action termed constitutive activity 
(Barker et al., 1994).  RNA editing dramatically reduces constitutive activity of the 5-
HT2C receptor (Niswender et al., 1999; Herrick-Davis et al., 1999), therefore, we 
determined if the C23S polymorphism altered the constitutive activity of the 5-HT2C 
receptor.  COS-7 cells were transiently transfected with increasing concentrations of C23 
or S23 5-HT2C-INI or 5-HT2C-VSV receptors and 3H-IP formation was measured in the 
absence of agonist for 30 minutes.  For the 5-HT2C-INI expressing cells, 3H-IP formation 
increased as the DNA concentration increased.  However, there was no significant 
difference between cells expressing C23 or S23 5-HT2C-INI receptors (Fig. 19).  Similar 
results were observed in cell lines expressing 5-HT2C-VSV receptors except constitutive 
activity was lower (Fig. 20), which agrees with previous studies (Herrick-Davis et al., 
1999).   
Because cell types may differ in their signaling machinery, it was important to test 
an additional cell type.  Therefore, we measured basal [3H]-IP formation in HEK293 cells 
expressing C23 or S23 5-HT2C-INI receptors.  Under basal conditions, expression of C23 
or S23 5-HT2C-INI receptors (at 4.7±0.6 pmol/mg) significantly increased [3H]-IP 
production compared to vector alone.  However, there was no difference in basal activity 
between C23 and S23 5-HT2C-INI receptors (Fig. 21).  Clozapine, a 5-HT2C receptor 
inverse agonist (Herrick-Davis et al., 2000), reversed the constitutive activity of C23 and 
S23 receptors to the same extent (Fig. 21).  HEK293 cells expressing C23 or S23 5-HT2C- 
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Figure 19: Constitutive activity of C23 and S23 5-HT2C-INI receptors 
Basal [3H]-IP formation was measured after 30 minutes according to the Materials and 
Methods section.  COS-7 cells were transiently transfected with increasing concentrations 
of C23 5-HT2C-INI or S23 5-HT2C-INI cDNAs (0.25-1.0 µg).  Overall, the slopes of the two 
lines were not different: F=0.48.  Data represent three independent experiments 
performed in duplicate. 
 
76 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Constitutive activity of C23 and S23 5-HT2C-VSV receptors 
COS-7 cells were transiently transfected with increasing concentrations of C23 5-HT2C-
VSV or S23 5-HT2C-VSV cDNAs (0.25-1.0 µg).  Overall the slopes were not significantly 
different: F=0.00.  Data represent three independent experiments performed in duplicate. 
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Figure 21: Constitutive activity of C23 and S23 5-HT2C-INI receptors in HEK293 cells 
HEK293 cells were transfected with 0.5 µg of 5-HT2C-INI cDNA.  Average receptor 
expression was 4.7 ± 0.6 pmol/mg protein.  Data represent the mean ± S.D. from six 
experiments each performed in triplicate.  +p<0.01 vs Vector; *p<0.01 vs Basal.  There 
was no significant difference between C23 and S23. 
78 
INI receptors at 10.4 ± 0.4 pm/mg protein also showed no significant differences in 
constitutive activity (data not shown). 
Agonist-promoted 3H-IP formation was evaluated in cells transiently expressing 
C23 or S23 5-HT2C-INI receptors to determine if there are differences in agonist potencies 
to activate PLC.  EC50 values from three independent experiments for C23 and S23 were 
1.1 ± 0.2 nM and 1.4 ± 0.5 nM, respectively, showing no significant differences in 
potency (Fig. 22).  The hallucinogen DOI also yielded similar results between C23 and 
S23 receptors with EC50 values of 3.1 ± 0.8 nM and 6.3 ± 0.9 nM, respectively (Fig. 23).  
We also evaluated 5-HT in HEK293 cells expressing C23 or S23 5-HT2C-INI receptors.  
EC50 values from three independent experiments were 2.4 ± 0.5 nM for C23 and 1.9 ± 0.6 
nM for S23 5-HT2C-INI receptors, again showing no significant difference in 5-HT 
potency (Fig. 24).   
 
Dimerization of the 5-HT2C-INI receptor is not altered by the C23S polymorphism 
 Fluorescence resonance energy transfer (FRET) experiments were performed to 
determine if the C23S polymorphism alters 5-HT2C receptor homodimerization.  
Acceptor photobleaching was used to measure FRET in selected regions of plasma 
membrane from 12 cells expressing C23 5-HT2C-INI/CFP (donor) and C23 5-HT2C-INI/YFP 
(acceptor) and 12 cells expressing S23 5-HT2C-INI/CFP and S23 5-HT2C-INI/YFP.  FRET 
efficiency was significantly correlated with the donor/acceptor ratio for cells expressing 
C23 and S23 5-HT2C-INI receptors (Fig. 25).  Since FRET efficiency is dependent on the 
donor/acceptor ratio, the cells were divided into three groups based on these ratios and 
 
79 
 
 
 
 
 
 
 
Figure 22: 5-HT stimulation of phospholipase C at C23 and S23 5-HT2C-INI receptors 
NIH-3T3 fibroblasts transiently transfected with C23 5-HT2C-INI or S23 5-HT2C-INI cDNA 
were stimulated with 5-HT for 30 minutes.  Receptor densities were 456 ± 137 fmol/mg 
and 492 ± 172 fmol/mg for C23 and S23, respectively.   
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Figure 23: DOI stimulation of phospholipase C at C23 and S23 5-HT2C-INI receptors 
NIH-3T3 fibroblasts were transiently transfected with C23 5-HT2C-INI or S23 5-HT2C-INI 
cDNA and stimulated with DOI for 30 minutes.  Receptor densities were 594 ± 78 
fmol/mg for C23 and 413 ± 91 fmol/mg for S23.   
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Figure 24: 5-HT stimulation of phospholipase C at C23 and S23 5-HT2C-INI receptors 
in HEK293 cells   
HEK293 cells were transiently transfected with C23 or S23 5-HT2C-INI cDNA and 
stimulated with 5-HT for 30 minutes.   
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Figure 25: Homodimerization of C23 and S23 5-HT2C-INI receptors 
FRET was measured on the plasma membrane of HEK293 cells expressing C23 or S23 5-
HT2C-INI/CFP and 5-HT2C-INI/YFP receptors.  Relationship between FRET efficiency and 
donor/acceptor ratio (donor fluorescence divided by acceptor fluorescence) measured in 
12 cells expressing C23 or S23 5-HT2C receptors.   
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the mean FRET efficiency for each group was calculated (Table 6).  This was done to 
provide a meaningful comparison of C23 and S23 FRET efficiencies from cells with 
similar donor/acceptor ratios.  The results presented in Table 7 indicate that there was no 
difference in FRET efficiencies for C23 and S23.  FRET efficiency was independent of 
acceptor fluorescence (Fig. 26), indicating that FRET was independent of receptor 
expression level.  
 
Discussion 
The human 5-HT2C receptor mRNA undergoes A-to-I editing at 5 positions 
termed A, B, C, D, and E in the second intracellular loop of the receptor (Burns et al., 
1997; Niswender et al., 1998), a region involved in G-protein coupling (Niswender et al., 
1999; Arora et al., 1995; Visiers et al., 2001).  This receptor also has a number of SNPs in 
its promoter region (Yuan et al., 2000; Deckert et al., 2000) and one in the coding region 
(Lappalainen et al., 1995).  The present study focused on the SNP in the coding region 
which converts a cysteine to a serine at the 23rd amino acid in the N-terminus of the 
receptor.  This polymorphism occurs at a frequency of 13% in the Caucasian population 
(Lappalainen et al., 1995) and has been associated with numerous disease symptoms (for 
a recent review see Sanders-Bush et al., 2003).  Therefore, this paper addresses the 
functional consequences of the combination of RNA editing and the C23S polymorphism 
in the human 5-HT2C receptor.  A recent study by Okada et al (2004) demonstrated that 
the C23S SNP in the 5-HT2C receptor was functional, but here we report that the C23S 
SNP has no functional consequences, even when expressed in the VSV backbone, the 
most prominent isoform in the human brain.  These negative data, which were 
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Table 6: Relationship between FRET efficiency and donor/acceptor ratio 
FRET efficiencies measured in 12 HEK293 cells expressing C23 5-HT2C-INI/CFP + 5-
HT2C-INI/YFP or S23 5-HT2C-INI/CFP + 5-HT2C-INI/YFP (data from Figure 6a) were 
divided into three groups based on their donor/acceptor ratios (D/A). Data represent the 
mean ± S.E.M for the number of cells per group as indicated (n). 
 
C23 S23 
D/A %FRET  n D/A %FRET n 
0.90 ± 0.03 12.1 ± 0.2 3 0.89 ± 0.04 12.6 ± 0.9 4 
0.74 ± 0.04 19.8 ± 1.3 5 0.72 ± 0.07 20.2 ± 0.2 4 
0.54 ± 0.03 29.3 ± 1.5 4 0.55 ± 0.02 28.7 ± 2.9 4 
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Figure 26: Relationship between FRET efficiency and acceptor fluorescence for C23 
and S23 5-HT2C-INI receptors 
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reproduced in three cell lines and two laboratories, may suggest a different strategy for 
future genetic studies. 
Non-synonymous SNPs change the amino acid coding potential of a protein 
which may lead to an alteration in conformation of the protein.  This amino acid change 
can lead to an unstable protein that may be retained in the endoplasmic reticulum, thereby 
decreasing the amount of receptor on the surface available to interact with agonist 
(Wenkert et al., 1996; Morello et al., 2000).  The current study demonstrated that S23 5-
HT2C-INI receptors were localized very similar to C23 5-HT2C-INI receptors.  This was first 
examined by immunofluorescence combined with confocal imaging in HEK293 cell 
transients.  In order to answer more quantitatively whether the C23S SNP altered cell 
surface expression, cellular distribution was evaluated by cell surface biotinylation and 
isolating biotinylated surface proteins with streptavidin beads.  Probing immunoblots 
with a human 5-HT2C receptor antibody revealed equivalent levels of cell surface 
biotinylated protein in cells expressing the C23 or S23 5-HT2C-INI or 5-HT2C-VSV 
receptors.  All isoforms of the protein migrated at similar molecular weights as diffuse 
bands revealing that glycosylation is intact.  This agrees with previous studies of the 5-
HT2C receptor (Backstrom et al., 1997).  All together, these data suggest that protein 
processing and targeting are not altered by the C23S polymorphism. 
 The present study found that NIH-3T3 fibroblasts and HEK293 cells expressing 
S23 5-HT2C receptors were able to bind all ligands tested with similar affinities to that of 
C23 5-HT2C receptors.  In NIH-3T3 fibroblasts with equivalent receptor densities, 
competition binding curves for the agonists 5-HT, DOI, and m-CPP were shallow and 
best fit by a two-site model, suggesting that both C23 and S23 receptors can bind agonists 
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in the G-protein coupled and uncoupled states.  In order to test this hypothesis, a non-
hydrolyzable GTP analog, Gpp(NH)p, was added.  This addition of Gpp(NH)p shifted 
agonist competition curves to a single low affinity state, confirming that agonists were 
binding to the receptors with high and low affinity and that agonist high affinity binding 
was not altered in cells expressing the S23 5-HT2C receptors.  In an independent study, 
HEK293 cells were transiently transfected with C23 or S23 5-HT2C-INI receptor cDNA 
and agonist competition binding experiments were performed.  Again, none of the ligands 
tested showed a significant difference between C23 and S23 receptors (data not shown).  
Okada et al. (2004) demonstrated increased high affinity binding to 5-HT and m-CPP at 
S23 5-HT2C-INI receptors.  Although statistically significant, the differences found were 
small and may not be biologically significant.  Both mutagenesis and biochemical studies 
with a variety of class A GPCRs suggest that receptor activation by ligand binding 
involves disruption of strong ionic interactions in transmembrane helices 3 and 6 
(reviewed in Kroeze et al., 2003).  These studies are consistent with our data showing that 
a SNP in the N-terminus of the 5-HT2C receptor does not alter binding.  It is very unlikely 
that a SNP in the N-terminus would change the binding affinity of the 5-HT2C receptor 
unless there was an extensive conformational change.  If a conformational change such as 
this did take place, one might expect that trafficking or G-protein coupling would be 
altered, but we did not observe this.  Therefore, our data lead us to conclude that the S23 
allele does not alter ligand binding.  
The 5-HT2C receptor has been shown to exhibit prominent constitutive activity 
(Barker et al., 1994), defined as the ability of a receptor to bind its cognate G-protein and 
activate signaling in the absence of agonist.  Constitutive activity in the 5-HT2C receptor 
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has been shown to be dramatically reduced in the 5-HT2C receptor as a consequence of 
RNA editing (Niswender et al., 1999; Herrick-Davis et al., 1999).  In the current studies, 
we found that COS-7 cells transiently transfected with increasing concentrations of C23 
or S23 5-HT2C receptor cDNA elicited [3H]-IP production in the absence of agonist.  
Basal activity was greater in cells expressing 5-HT2C-INI than 5-HT2C-VSV receptors in 
agreement with previous studies (Niswender et al., 1999; Herrick-Davis et al., 1999).  
However, there was no significant difference in basal activity between C23 and S23 
receptors, whether in the INI or VSV backbone.  To address the possibility that a 
functional consequence could be cell-type dependent, we examined constitutive activity 
in HEK293 cells and found no difference at multiple receptor densities.  Okada and his 
group (Okada et al., 2004) found that S23 5-HT2C-INI receptors had increased constitutive 
activity compared to wildtype receptors using in vitro reconstitution of receptor 
expressed in Sf9 insect cells with squid Gαq and bovine Gβγ subunits.  In the current 
study, Okada’s differences found utilizing purified proteins in vitro are not reproduced in 
intact cells; our studies showed that C23 and S23 5-HT2C receptors have similar activities 
in intact mammalian cells. 
 In the present study, PLC activation was examined in NIH-3T3 transients to see 
how C23 and S23 5-HT2C-INI receptor downstream signaling compared.  Activation with 
5-HT and DOI gave similar dose response curves at C23 and S23 receptors with no 
differences in potency or maximal response.  This was also replicated in stable cell lines 
expressing the INI or VSV isoform (data not shown).  In addition, HEK293 cells 
transiently expressing 5-HT2C-INI receptor showed no difference in the potency or 
maximal response to 5-HT.  Taken together, these data suggest that the C23 and S23 5-
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HT2C receptors have comparable signaling capabilities.  However, it is possible that there 
could be differences in other pathways that the 5-HT2C receptor is known to activate such 
as PLD or PLA2. 
The 5-HT2C receptor has been reported to form homodimers/oligomers (Herrick-
Davis et al., 2004), as has been found for other G-protein-coupled receptors (reviewed in 
Angers et al., 2002).  5-HT2C receptor dimerization can be visualized on the plasma 
membrane of living cells using FRET combined with confocal microscopy (Herrick-
Davis et al., 2004).  FRET occurs when the light emitted from a laser-excited donor is 
transferred to an acceptor, resulting in excitation of the acceptor and quenching of the 
donor.  In order for this interaction to occur, the donor and acceptor must have 
overlapping emission and excitation spectra, and they must be within 1-10nm of each 
other with their dipoles oriented appropriately for energy transfer (Förster, 1948).  When 
the acceptor is removed by photobleaching, the donor becomes de-quenched and FRET is 
measured as an increase in donor fluorescence.  In the present study, FRET efficiencies 
were measured by acceptor photobleaching on the plasma membrane of cells expressing 
C23 or S23 5-HT2C-INI receptors to determine if the C23S polymorphism alters the ability 
of the receptor to form homodimers/oligomers.  FRET can result from specific 
protein:protein interactions, such as dimer/oligomer formation (receptors in a clustered 
distribution), or from high levels of donor and acceptor in close enough proximity to 
produce FRET because they are tightly packed in a small region of membrane (random 
proximity effect).  Recent studies examining these two models have suggested that FRET 
resulting from random proximity of donor and acceptor is dependent on the amount of 
acceptor expressed on the plasma membrane, while FRET resulting from clustered 
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proteins should be independent of acceptor expression levels and dependent on the ratio 
of donor to acceptor (Kenworthy and Edidin, 1998; Wallrabe et al., 2003).  In the present 
study, FRET efficiency was dependent on the donor/acceptor ratio and independent of 
acceptor expression, suggesting that FRET resulted from receptors in a clustered 
distribution on the plasma membrane and not from receptor over-expression.  When 
FRET efficiencies were compared in cells with similar donor/acceptor ratios, there was 
no difference in the amount of FRET measured on the plasma membrane of cells 
expressing C23 or S23 5-HT2C-INI receptors.  These results suggest that the C23S 
polymorphism has no effect on 5-HT2C receptor homodimerization.  However, it is not 
possible to determine whether 5-HT2C receptor homodimers are formed once the 
receptors reach the plasma membrane or if they form intracellularly and are transported 
to the plasma membrane as homodimers. 
The current study is important to the field given the number of association studies 
examining the C23S polymorphism with neuropsychiatric disorders.  This SNP occurs at 
a frequency 13% in the Caucasian population (Lappalainen et al., 1995) and has been 
reported at even higher frequencies in other populations (Lerer et al., 2001; Masellis et 
al., 1998).  The C23S polymorphism has been found to be positively associated with 
disease symptoms and drug responses in schizophrenia, unipolar depression, bipolar 
disorder and Alzheimer’s disease (for recent review, see Sanders-Bush et al., 2003).  The 
underlying causes of these associations are unknown.  Since there appears to be no 
biologically relevant difference in the function of the C23S SNP, positive associations 
may be due to linkage disequilibrium between this SNP and the causative SNP which 
could be in another gene or in another position of the 5-HT2C receptor gene.   
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In summary, using multiple stable and transient cell lines generated from different 
plasmid constructs and in different laboratories, we have data from three mammalian 
cell-types showing no functional consequence of the C23S polymorphism in the human 
5-HT2C receptor in either the non-edited INI or the edited VSV isoform, which is the 
principal isoform in the human brain (Niswender et al., 1999).  No differences between 
the C23 versus the S23 allele were detected in a number of experimental parameters, 
including radioligand binding, immunolocalization, cell surface targeting, receptor 
dimerization, constitutive activity and agonist-promoted phosphoinositide hydrolysis.  
These results do not agree with a recent report by Okada et al (2004), which showed that 
the S23 variant has increased constitutive activity in reconstitution experiments, utilizing 
5-HT2C receptors expressed in insect cells.  Although constitutive activity was increased 
in the S23 receptor variant in this unnatural preparation, our results show that this 
difference is not reproduced in intact mammalian cells.  Given that the 5-HT2C receptor is 
only expressed in brain, it would be interesting to examine the properties of the S23 
variant in a neuronal cell line.1 
 
 
 
 
 
                                                 
 
1 This chapter has been pubished in the Pharmacogenomics Journal (2005):  Hugh M. Fentress, Ellinor 
Grinde, Joseph E. Mazurkiewicz, Jon R. Backstrom, Katharine Herrick-Davis, and Elaine Sanders-Bush. 
Pharmacological Properties of the Cys23Ser Single Nucleotide Polymorphism in Human 5-HT2C Receptor 
Isoforms. Pharmacogenomics J. (in press) 
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CHAPTER III 
 
GENETIC ANALYSIS OF 5-HT2C RECEPTORS IN UNIPOLAR DEPRESSION 
 
Introduction 
 Unipolar depression, also known as major depressive disorder (MDD), is a severe 
psychiatric disease with lifetime prevalence between 13-19% (Lehtinen and Joukamaa, 
1994).  The importance of a genetic component is widely accepted (Kendler et al., 1994), 
but the mode of inheritance is complex and non-Mendelian.  Pharmacological studies 
have suggested that depression is associated with an impairment of brain 
neurotransmitters; a role for 5-HT is based upon the efficacy of selective serotonin 
reuptake inhibitors (SSRIs) in the treatment of depression.  In addition, many 
antidepressants such as fluoxetine, norfluoxetine, citalopram, amitriptyline, and 
mianserin have high affinity for the 5-HT2C receptor (Palvimaki et al., 1996; Fentress et 
al., 2005), although anatogonism at this receptor is not predictive of antidepressant utility.  
Behavioral studies by Cryan and Lucki (2000) showed that, like fluoxetine, selective 5-
HT2C receptor agonists are able to decrease immobility and increase swimming in the rat 
forced swim test, a model of antidepressant efficacy.  More evidence for the involvement 
of the 5-HT2C receptor in depression is that blockade of 5-HT2C receptors has been shown 
to potentiate the effects of SSRIs in rats (Cremers et al., 2004).  All together, these 
studies suggest that genetic alterations in 5-HT2C receptors may increase the 
susceptibility of an individual to develop MDD or an endophenotype within depression. 
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 A non-synonymous SNP in the coding region of the 5-HT2C receptor has been 
identified that converts a cysteine (Cys) to a serine (Ser) at the 23rd amino acid position 
(Cys23Ser) (Lappalainen et al., 1995).  The Cys23Ser polymorphism has been shown to 
associate with individuals who have late onset Alzheimer’s disease with visual 
hallucinations and hyperphagia (Holmes et al., 1998), in addition to schizophrenia 
patients with tardive diskinesia (Segman et al., 2000).  Recently, a genetic component of 
MDD was identified (Sullivan et al., 2000).  However, there have been only two 
association analyses of the Cys23Ser SNP in MDD.  One of these studies, performed on a 
population of European subjects, found a positive association between the occurrence of 
the Ser23 allele and MDD (Lerer et al., 2001).  This SNP has also been reported to occur 
at higher frequencies in African American patients (Masellis et al., 1998; Glatt et al., 
2004).  Since MDD is a complex disorder, we hypothesized that the Cys23Ser SNP may 
be associated with an endophenotype of depression.  The term “endophenotype” is 
defined as an internal phenotype that fills the gap between available descriptors, the 
genes, and the elusive disease processes (Gottesman and Shields, 1973).  Therefore, the 
goal of this study was to perform exploratory analyses on the frequency of non-
synonymous SNPs in the 5-HT2C receptor in depression and their association with 
endophenotypes within the disease.  
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Methods 
Depressed Subjects 
110 depressed patient samples were collected through collaboration with Dr. 
Richard Shelton at Vanderbilt University, and were obtained using proper informed 
consent and protocols approved by the Institutional Review Board.  All subjects were 
persons with DSM-IV MDD (unipolar type).  Participants were self-referred or referred 
by professionals to the clinic. About 80% of the patients were Caucasian, 15% were 
African-American, and 5% were underrepresented minorities.  This reflects the 
distribution of the population in the Nashville, TN area.  Patients were (1) over the age of 
18; and (2) willing and able to give written informed consent. 
Any subjects were excluded if they met any of the following:  (1) bleeding 
disorder; (2) evidence of any medical disorder or condition that would exclude 
participation, in the judgment of the investigator; (3) current treatment with 
catecholaminergic antihypertensive medication (including reserpine, beta-blockers, 
clonidine, alphamethyldopa, etc.; diuretics, ACE inhibitors and calcium channel 
inhibitors were allowed); (4) history of significant endocrine disease (including Cushing's 
Disease, Nelson's disease, or other HPA abnormality, or hypothyroidism); (5) pregnancy 
or lactation; or (6) clear indication of secondary gain (e.g., court ordered treatment or 
compensation issues). 
Persons diagnosed with major depression were determined to be free of: (1) a 
history of bipolar affective disorder (bipolar I, II, or mixed type) or cyclothymia; (2) any 
history of non-affective psychotic Axis I disorders, including schizophrenia, 
schizoaffective disorder, delusional disorder, psychotic disorder due to a substance or 
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medical condition, or psychotic disorder NOS; (3) current nonpsychotic Axis I disorder; 
e.g., generalized anxiety disorder; panic disorder, phobic disorder, obsessive-compulsive 
disorder, eating disorder, etc., if currently present and if the predominant aspect of the 
clinical presentation.  In addition, all patients were free of (1) antisocial, borderline, or 
schizotypal Axis II personality disorder; (2) subnormal intellectual potential (estimated 
IQ below 80); or (3) history of substance abuse in the past six months or substance 
dependence in the past twelve months.  If suicide risk or psychosis was present, steps 
were taken to ensure the safety of subjects (e.g., hospitalization, if appropriate).  After a 
positive MDD diagnosis, several patient interviews were conducted, enabling a secondary 
diagnosis of either atypical or melancholic depression.  In addition, the MDD 
endophenotypes of each patient were recorded for subsequent SNP association studies 
(Table 7). 
 
African Subjects 
 Normal African subjects were recruited from Accra, Ghana.  Recruitment was 
done at the clinics of Department of Medicine at the Korle Bu Teaching Hospital of 
University of Ghana Medical School, the Mamprobi Hypertension Clinic, and the 
Kaneshie Market.  Subject recruitment protocols were approved by the Institutional 
Review Board of Meharry Medical College and the Ethical Committee of the University 
of Ghana School of Medicine. 
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Table 7:  Endophenotypes examined in Major Depressive Disorder patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MDD Endophenotypes 
MDD subtype 
MDD age of onset 
Recurrent or single episode MDD 
MDD severity 
Past/present antidepressant treatment 
Patient history of other psychiatric disease 
Patient history of substance abuse 
Presence of personality disorders 
Family history of psychiatric disease 
Family history of substance abuse 
Depressed mood 
Guilt 
Suicide (ideation and attempts) 
Early/middle/late insomnia 
Hypersomnia (hours of additional sleep) 
Napping 
Anhedonia 
Retardation 
Agitation 
Psychic or somatic anxiety 
Change in appetite 
Energy 
Libido 
Hypochondriasis 
Weight loss/gain 
Degree of insight 
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DNA Extraction 
DNA was extracted blood samples (6-12 mL) using the Puregene genomic DNA 
extraction kit per manufacturer’s instructions (Gentra Systems, Minneapolis, MN). 
 
DNA Analysis 
For DNA genotyping, one set of PCR amplification primers (Urogentec, West 
Chester, PA) and a single sequencing primer (DNA core, Vanderbilt University, 
Nashville, TN) were designed and prepared for each SNP.  The PCR primers consisted of 
one biotinylated primer and one unbiotinylated primer that were designed to amplify a 
region of the 5-HT2C receptor genomic DNA of less than 200 nucleotides, containing the 
SNP of interest.  Following amplification of the target region, the biotinylated amplicons 
were annealed to streptavidin-coated agarose beads and separated from unbiotinylated 
strands by vacuum filtration.  The isolated biotinylated strands were then washed and 
transferred to 96-well plates and buffers (Pyrosequencing AB, Uppsala, Sweden), 
sequencing primer, and polymerase were added to each well.  The sequencing primer was 
designed to anneal just 5′ (~10 nucleotides) of the polymorphism.  The target sequence 
downstream of the sequencing primer was entered into the pyrosequencing computer 
(with “false” nucleotides as controls).  Based upon this sequence, dNTPs were 
automatically released into each well one nucleotide at a time.  If a nucleotide was 
complementary to the biotinylated strand, it was incorporated and caused the release of 
pyrophosphate.  This pyrophosphate was converted to ATP by sulfurylase, and this ATP 
was used as energy by luciferase to convert luciferin to oxyluciferin, generating light 
(Fig. 27).  Each flash of light was detected by the pryrosequencing camera and used to  
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generate a mini sequence report (pyrogram, Fig. 28) that was analyzed for the presence of 
SNPs. 
 
Statistical Analysis 
 Genotypes and allele frequencies were compared across all patient 
endophenotypes and drug treatment groups by Fisher’s exact test and logistic regression 
analysis. 
 
Results and Discussion 
In the present study of 110 depressed patients, the allele frequency of the 
Cys23Ser polymorphism in the 5-HT2C receptor was not different from that published in 
the literature.  There were no homozygous females in our population while there were 
eight hemizygous males (Table 8).  The allele frequency of the polymorphic Ser23 allele 
was 12% which is not different from the initial value reported for normal controls 
(Lappalainen et al., 1995).  However, this SNP occurs at varying frequencies in different 
populations (Table 9).  Recently it was reported that the Cys23Ser SNP occurs at 40% in 
African-American populations (Masellis et al., 1998; Glatt et al., 2004).  In order to 
evaluate this further, African samples were obtained from a collaborator Scott Williams 
(Vanderbilt University) and analyzed for the polymorphism.  If this polymorphism truly 
occurs at three times the frequency in African populations relative to Europeans, it could 
dramatically skew the association analyses from mixed samples especially if there are 
large numbers of African-Americans.  We found the allele frequency of the Ser23 allele  
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Table 8:  Cys23Ser genotype in MDD patients 
The HTR2C gene is on the X chromosme, therefore the Cys/- genotype represents          
hemizygous males for Cys23; Ser/- genotype represents hemizygous males for Ser23.  
Percent equals the percentage of the respective genotype for the population as a whole. 
 
5-HT2C Receptor 
Genotype 
Number of Patients Percent 
Cys/- 34 30.9 
Ser/- 8 7.2 
Cys/Cys 53 48.2 
Cys/Ser 15 13.7 
Ser/Ser 0 0 
Total 110 100 
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Table 9:  Frequency of Cys23Ser SNP in different populations 
Population Frequency Reference 
Caucasian  13% Lappalainen et al., 1995 
African-American 40% Masellis et al., 1998; Glatt et 
al., 2004 
Japanese 1.9% Kusumi et al., 2004 
German 16.9% Lerer et al., 2001; Stefulj et al., 
2004 
Slavic 16.1% Stefulj et al., 2004 
Belgian 21.1% Lerer et al., 2001 
Bulgarian 10.3% Lerer et al., 2001 
Greek 24.6% Lerer et al., 2001 
Italian 14.2% Lerer et al., 2001 
Scottish 9.2% Lerer et al., 2001 
Swedish 19.2% Lerer et al., 2001 
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to be 39% in the African population (Table 10), agreeing with the previous reports in 
African-Americans (Masellis et al., 1998; Glatt et al., 2004).  Over 50% of the subjects 
had a Ser23 allele and there were 4 homozygous females in the sample as opposed to zero 
in the depressed population.  An examination of the ethnic distribution of our depressed 
patients (Table 11) revealed that the majority were Caucasian (85%), making it unlikely 
that there were enough non-Caucasians to cause stratification. 
 Major depressive disorder is a complex disease, involving many genes and 
neurotransmitter systems in combination with environmental factors.  Therefore, it is 
unlikely that a SNP in one gene will cause depression.  However, it is more probable that 
a single SNP may be responsible for an endophenotype within depression (Table 7).  
Thus, we examined the association of the Cys23Ser polymorphism in the 5-HT2C receptor 
with endophenotypes of unipolar depression.  There were positive associations of the 
minor allele (Ser23) with decreased early and late insomnia (Table 12).  The association 
with middle insomnia was weaker and not significant (Table 12).  These results suggest 
that the Ser23 is protective and decreases insomnia in depressed patients.  5-HT2C 
receptor antagonists produce dose dependent increases in slow wave sleep (SWS) in 
humans and rats (Sharpley et al., 1990; Dugovic and Wauquier, 1987) while 5-HT2C 
agonists inhibit SWS in rats (Dugovic, 1992).  Futhermore, the 5-HT2 antagonist 
ritanserin has been found to have different functional responses in depressed patients 
compared to controls.  For example, the dose dependent increase in SWS observed with 
ritanserin in normal individuals is reduced in depressed patients (Staner et al., 1992) 
suggesting an upregulation in 5-HT2 receptors in patients with depression, thereby 
leading to a blunted functional response (Smith et al., 2002).  Based on these  
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Table 10:  Cys23Ser genotype in African subjects 
The HTR2C gene is on the X chromosme, therefore the Cys/- genotype represents          
hemizygous males for Cys23; Ser/- genotype represents hemizygous males for Ser23.  
Percent equals the percentage of the respective genotype for the population as a whole. 
 
5-HT2C Receptor 
Genotype 
Number of Patients Percent 
Cys/- 34 36 
Ser/- 21 22 
Cys/Cys 12 13 
Cys/Ser 24 25 
Ser/Ser 4 4 
Total 95 100 
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Table 11:  Ethnicity of MDD patients 
Other category represents patients of mixed descent.  Percent equals the percent of the 
total population. 
 
Ethnicity Number of Patients Percent 
Caucasian 94 85 
African-American 7 6 
Asian 5 5 
Hispanic 1 1 
Other 3 3 
Total 110 100 
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Table 12:  Cys23Ser SNP associations with endophenotypes in MDD patients 
Analyses were performed on the entire depressed population (110 patients).  Coefficients 
were derived by ordinal logistic regression.  The coefficients represent the direction and 
magnitude of the associations.  p values were determined by the Wald test.  Asterisks (*) 
represent significance of the minor allele (Ser23) compared to patients with major allele 
(Cys23). 
 
Endophenotype Coefficients p value 
Early Insomnia -1.75 0.009* 
Middle Insomnia -1.12 0.086 
Late Insomnia -1.52 0.041** 
Somatic Anxiety 1.61 0.015*** 
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pharmacological studies, one possible interpretation of our results is that depressed 
patients with the Ser23 allele have decreased functional 5-HT2C receptors which might 
translate into increased SWS and decreased insomnia. 
Upon further analysis, we also found an association of Ser23 with increased 
somatic anxiety (Table 12).  Somatic anxiety is defined as physiologic concomitants of 
anxiety such as dry mouth, gas, indigestion, diarrhea, constipation, dizziness and 
sweating.  m-chlorophenylpiperazine (mCPP), a metabolite of the antidepressants 
trazodone and nefazodone is a non-selective 5-HT2C receptor partial agonist that causes 
anxiety and sympathetic nervous system arousal in humans (Abi-Saab et al., 2002; 
Broocks et al., 2001).  The anxiety like effect of mCPP in rats is blocked by specific 5-
HT2C antagonists (Blackburn et al., 1997).  When 5-HT2C receptor antagonists are 
administered alone, they produce anxiolytic-like behavior in various animal models 
(Kennett et al., 1996, 1997).  Kuhn et al. (2004) recently found differences in mCPP 
response in healthy subjects with and without the Cys23Ser SNP.  Subjects with the 
Cys23 allele had region cerebral blood flow (rCBF) increased in the left medial prefrontal 
cortex and decreased in the left anterior cingulate and right medio-temporal cortex, 
whereas subjects with the Ser23 allele showed an increase in rCBF in the left medio-
temporal cortex and a reduction of rCBF in the right medial prefrontal cortex (Kuhn et 
al., 2004).  Together, these data suggest that the Cys23Ser polymorphism is functionally 
relevant in humans, perhaps related to anxiety phenotypes. 
Since 5-HT2C Cys23Ser SNP occurs at various frequencies depending upon the 
ethnic population (Table 9), we reanalyzed the patient data using Caucasians only.  The 
Caucasian depressed patients continued to have strong associations of the Ser23 allele 
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with early and late insomnia (Table 13).  Additionally, we were now able to attain an 
association with middle insomnia (Table 13).  However, upon examining the 
endophenotype of somatic anxiety, the positive association was lost in the Caucasian 
patients (Table 13).  The loss of the association with somatic anxiety could be due to the 
reduced number of patients with the Ser23 allele after removing the non-Caucasian 
patients.  Alternatively, there may be increased anxiety among the other ethnicities and 
when these individuals are excluded, the association disappears.   
Taken together, the association data suggest that the Cys23Ser SNP in the human 
5-HT2C receptor may have functional consequences.  However, this conclusion conflicts 
with our functional data in cell lines.  One possible explanation for this discrepancy is 
that the Cys23Ser SNP is in linkage disequilibrium with the causative SNP which could 
be in the HTR2C gene or another gene.  Therefore, the associations that were found could 
be due to a SNP in a gene that is closely linked to the Cys23Ser SNP.   
There are several polymorphisms in the promoter region of the HTR2C gene 
(Table 2).  Two of these SNPs, -697 G/C and -759 C/T, have been shown to have 
functional consequences and to be associated with disease states (Table 3).  Therefore, 
we examined the occurrence of these SNPs in the depressed patient set.  The frequencies 
of the -697 G/C and -759 C/T polymorphisms were similar to the values previous 
reported in the literature (Table 14).  Analysis of the -697 G/C promoter SNP with 
endophenotypes in depressed Caucasians revealed positive associations of the minor 
allele (C) with somatic anxiety, early insomnia, and increased appetite (Table 15).  The -
759 minor allele (T) was associated with suicide attempts and the total score for the 
Hamilton Rating Scale for Depression (HRSD) items 1-17 in Caucasian depressed  
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Table 13:  Cys23Ser SNP associations with endophenotypes in Caucasian MDD 
patients 
Analyses were performed on Caucasian depressed patients (94 patients).  Coefficients 
were derived by ordinal logistic regression.  The coefficients represent the direction and 
magnitude of the associations.  p values were determined by the Wald test.  Asterisks (*) 
represent significance of the minor allele (Ser23) compared to patients with the major 
allele (Cys23). 
 
Endophenotype Coefficients p value 
Early Insomnia -2.42 0.003* 
Middle Insomnia -2.00 0.014** 
Late Insomnia -2.05 0.03*** 
Somatic Anxiety 1.07 0.14 
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Table 14:  Promoter SNP genotypes and frequencies in MDD 
The HTR2C gene is on the X chromosme, therefore the G/Y and C/Y genotypes 
represent hemizygous males for the major G and C alleles, respectively; C/Y and T/Y 
genotypes represent hemizygous males for the minor C and T alleles, respectivley.  
Percent equals the percentage of the respective genotype for the population as a whole. 
 
5-HT2C Receptor 
Genotype 
Number of Patients Percent 
-697 G/C -759 C/T -697 G/C -759 C/T -697 G/C -759 C/T 
G/- C/- 28 35 27 32 
C/- T/- 14 8 14 7 
G/G C/C 31 48 30 44 
G/C C/T 27 19 26 17 
C/C T/T 3 0 3 0 
Total 103 110 100 100 
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Table 15: -697 G/C SNP associations with endophenotypes in Caucasian MDD 
patients 
Analyses were performed on Caucasian depressed patients (94 patients).  Coefficients 
were derived by ordinal logistic regression.  The coefficients represent the direction and 
magnitude of the associations.  p values were determined by the Wald test.  Asterisks (*) 
represent significance of the minor allele (C) compared to patients with the major allele 
(G). 
 
Endophenotypes Coefficients p value 
Early Insomnia -0.93 0.015* 
Middle Insomnia -0.68 0.078 
Increased Appetite 0.87 0.034** 
Chronic Depressed Episode 0.86 0.07 
Somatic Anxiety 1.5 0.001*** 
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patients (Table 16).  These data suggest that there may be genetic linkage between the 
Cys23Ser and the -697 G/C polymorphisms in the 5-HT2C receptor given that they 
associate with the same endophenotypes in MDD. 
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Table 16: -759 C/T SNP associations with endophenotypes in Caucasian MDD 
patients 
Analyses were performed on Caucasian depressed patients (94 patients).  Coefficients 
were derived by ordinal logistic regression.  The coefficients represent the direction and 
magnitude of the associations.  p values were determined by the Wald test.  Asterisks (*) 
represent significance of the minor allele (T) compared to patients with the major allele 
(C). 
 
Endophenotpes Coefficients p value 
Suicide Attempts 1.73 0.014* 
HRSD Score 1-17 1.82 0.03** 
Increased Appetite 0.84 0.09 
Somatic Anxiety 0.89 0.08 
 
 
 
 
 
 
114 
CHAPTER IV 
 
SUMMARY AND FUTURE DIRECTIONS 
 
The identification of only 30,000 genes with the completion of sequencing the 
human genome reveals the importance of mechanisms for generating molecular and 
genetic diversity.  One way to achieve molecular diversity is through post-transcriptional 
events such as RNA editing.  The 5-HT2C receptor is the only GPCR that has been shown 
to undergo RNA editing, which generates functionally distinct protein isoforms from a 
single gene.  Another way to achieve diversity is through genetic modifications: SNPs, 
deletions, insertions, and repeats.  SNPs are the most common type of genetic variation 
and by definition occur at a frequency greater than 1% (Wang et al., 1998).  Within the 
coding region of the human 5-HT2C receptor gene are two SNPs (Lappalainen et al., 
1995; Gibson, et al., 2004) whereas three have been reported in the promoter region 
(Yuan et al., 2000).  When I initiated my research, the Cys23Ser polymorphism had been 
extensively examined in association studies, but the protein had not been characterized 
functionally.  In this thesis, I report the results of functional analyses of this SNP in a 
variety of assays.   
Despite extensive investigations in three different cell types, we did not find any 
evidence of altered function of the Cys23Ser SNP; however, we did find positive 
associations with this SNP in depressed patients, including the subphenotypes of 
insomnia and anxiety.  Therefore, the Cys23Ser polymorphism may be in linkage 
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disequilibrium with another SNP, leading to the observed associations with depressive 
symptoms. 
5-HT2C receptors with the Cys23Ser SNP did not have any difference in cellular 
distribution, even in edited backbones.  This was demonstrated by immunofluorescence 
and confirmed by surface biotinylation combined with western blotting.  The banding 
pattern of the receptors were very similar, migrating as broad bands around 50 kDa, 
indicating that glycosylation is intact.  Although these results suggest that trafficking and 
cell targeting is not altered in receptors with the Cys23Ser polymorphism, it is still 
possible that there are small changes that are beyond the sensitivity of these assays.  In 
the immunofluorescence experiments, receptors that have a CFP tag fused to their C-
terminals were overexpressed in HEK293 cells.  Although these receptors were still able 
to signal, the tag may change the conformation without altering function, but eliminating 
any differences in conformation that may be present in native receptors.  Morello et al. 
(2002) showed that treatment of cells expressing the mutant vasopressin receptors with 
antagonists caused increased surface expression, presumably via binding and stabilizing 
partially folded mutant receptors.  Pilot experiments of possible rescue of functional 
receptors by pretreatment of cells expressing 5-HT2C receptor variants with 5-HT2C 
antagonists were negative.  It would be interesting to pursue such studies in more direct 
assays of cell surface receptors; however, there was very little 5-HT2C receptor protein on 
the cell surface in our biotinylation experiments.  The large intracellular pool of receptors 
may be due to the receptor’s high constitutive activity.  The prominent intracellular 
localization, combined with the limitations of the assays, make subtle changes difficult to 
accurately quantitate.   
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Our inability to find differences in binding, signaling, and constitutive activity at 
Cys23Ser 5-HT2C receptors could be due to a number of reasons.  We used NIH-3T3 
fibroblasts that are derived from mouse and COS-7 cells, derived from monkeys.  
HEK293 cells were used in some studies but these cells are derived from the human 
embryonic kidney.  Since the 5-HT2C receptor is only expressed in the brain, it would be 
interesting to examine the properties of receptor variants in a neuronal cell line.  Another 
potential caveat is the fact that we only examined one signaling pathway of the 5-HT2C 
receptor.  This receptor has also been shown to activate PLD and PLA2 (McGrew et al., 
2002; Berg et al., 1996, 1998) and interact with the G13 protein (Price et al., 2001).  In 
order to definitively conclude that no functional consequences result from the Cys23Ser 
polymorphism, examination of these pathways should be conducted.  New technology 
now allows us to examine many pathways and genes at once.  SuperArray Bioscience 
corporation has focused DNA microarrays with human G-protein subunits and their 
downstream signaling and effector proteins, making gene expression profiling of G-
protein signaling feasible.  Alternatively, Kinexus offers technology to track 31 
phosphorylation sites of different proteins (as an indirect index of activation) in lysates 
from cells or tissues.  Future studies should use these methods to further compare the 
function of the Cys23Ser SNP in 5-HT2C receptor isoforms.  If an alteration is found, 
more experiments could then be performed to determine the mechanism of the alteration. 
Although no functional consequences of the Cys23Ser SNP were found in our in 
vitro studies, we did find associations with the Ser23 allele in MDD.  Subjects with Ser23 
had increased anxiety and reduced early and late insomnia.  Because the frequency of this 
SNP varies across ethnic populations, we re-analyzed the data with Caucasians only; 
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some of the associations changed in this analysis.  These changes could be a result of the 
small sample size or an altered frequency of the SNP in the population that was removed.  
This suggests that one has to be careful when analyzing association data on this SNP with 
mixed populations.  The fact that we found associations in MDD and no change in 
functional assays in cells implies that the Cys23Ser polymorphism in the human 5-HT2C 
receptor may be in linkage disequilibrium with a functional SNP.  Likely candidates are 
the promoter polymorphisms in the 5-HT2C receptor.  Although our data show that the -
697 G/C promoter SNP is closely linked to the Cys23Ser SNP, it is not in complete 
linkage disequilibrium which leaves the possibility that other genes may be involved.  
The first genes that should be examined are those adjacent to the HTR2C gene on the X-
chromosome which includes LOC286528 (similar to heat shock protein C182) and 
IL13RA2 (interleukin 13 receptor, alpha 2) (Figure 29).  According to HapMap, this 
region of the X-chromosome has a very high degree of linkage disequilibrium in both 
Caucasian and African populations, suggesting that our hypothesis of the Cys23Ser SNP 
being in linkage disequilibrium with another SNP is likely correct.  However, analyses of 
the Perlegen Genome Browser revealed that African subjects have smaller blocks of 
linkage disequilibrium.  Therefore, future studies to locate other polymorphisms closely 
linked to the Cys23Ser SNP should use the Perlegen database of African subjects. 
Analyses of mitochondrial DNA and nuclear DNA markers have shown that 
Africa is the most genetically diverse region of the world (Tishkoff and Williams, 2002).  
As a result, we feel that the African subjects would be a powerful resource to screen for  
novel polymorphisms in the 5-HT2C receptor.  Normally, there is an average of one 
relatively common SNP and several less common SNPs (1% or less) in GPCRs of 
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average length (1000-1500 coding base pairs) (Sadee et al., 2001).  Therefore, a SNP 
discovery project may be necessary since the Cys23Ser SNP is the only common SNP in 
coding region of the 5-HT2C receptor, while the closely related 5-HT2A receptor has five  
119 
SNPs in its coding region.  However, since the 5-HT2C receptor undergoes RNA editing, 
generating up to 24 different protein isoforms, this receptor may have reached its 
requisite level of diversity via this mechanism.  In most SNP screenings, investigators 
only examine the exons of genes.  In the case of the 5-HT2C receptor, the introns are also 
important because the intron upstream of the edited sites is necessary for RNA editing of 
the transcripts.  Consequently, potential SNPs in the intron forming the RNA duplex may 
disrupt editing, increasing the risk for disease.  
In conclusion, the current work may change the way genetic association studies 
are performed, since it appears the Cys23Ser SNP in the 5-HT2C receptor is functionally 
silent.  This chapter outlines potential future experiments that will enhance our 
knowledge and understanding of the 5-HT2C receptor and its genetic alterations, and as a 
result may eventually lead to novel drug design and treatments based upon genetic 
backgrounds.  
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